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ABSTRACT OF DISSERTATION
An investigation of HHV6's impact on the cognitive progression and microglial changes in an
Alzheimer's disease cohort
The role of herpesviruses and, more specifically, HHV6 in the development of
Alzheimer’s disease (AD) and associated cognitive decline is still being investigated.
High ubiquity and prevalence in the population have led to a high degree of skepticism
about HHV6 as a potential contributor to cognitive decline and dementias. However,
recent evidence related to another herpesvirus, herpes simplex virus 1, suggests that
reactivation, not carriage, of the virus may be the key factor to explain the dissonance
between the virus’ ubiquity and contributions to dementias. With that in mind, we set out
to assess cases from the Sanders-Brown Center on Aging for evidence of HHV6
reactivation, both current and past, and how it relates to the rate of cognitive decline of
these patients in eight cognitive domains. HHV6 reactivation was assessed by 1) patient
self-report surveys, 2) anti-HHV6 serology, and 3) viral gene amplification via droplet
digital PCR (ddCPR) in post-mortem temporal lobe and cerebellum tissue. We extracted
RNA from these regions of postmortem tissue and performed the NanoString Human
Inflammatory Panel to assess gene expression changes concomitant with HHV6
carriage and reactivation. Based on these results, we more closely examined changes to
microglial activation and functional capacity based on the presence of HHV6. Finally, we
investigated the role T-cells played in the development of these changes and
subsequent pathology. Ultimately, we observed some predictive power from the patient
reported survey in terms of cognitive decline. Serological evidence of reactivation
showed no statistically significant relationship in any of the cognitive domains. ddPCR
revealed no significant correlations related to HHV6 carriage. NanoString gene
expression assays showed an upregulation of several neuroinflammatory genes, as well
as microglial markers and T-cell signaling cytokines in cases with HHV6. We observed
few differences in microglial activation, morphology, or phagocytosis as a function of
HHV6. We did observe evidence of HHV6 within some amyloid beta plaques examined,
and several T-cells surrounding plaques throughout diseased tissue with confirmed
HHV6. These results contribute to the ongoing debate surrounding the role of HHV6 in
the development of Alzheimer’s disease while providing evidence that suggests that
reactivation may not be a key factor connecting HHV6 to Alzheimer’s disease.
KEYWORDS: Neuropathology, viral reactivation, serology, neuroinflammation, cognitive
decline, phagocytosis
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CHAPTER 1: Introduction
Alzheimer’s disease:

Alzheimer’s disease (AD) is the most common cause of dementia and is clinically
characterized by learning and memory deficits that are progressive in nature and impact quality
of life1, 2. In addition to the physical and emotional toll of the disease on individuals afflicted and
their families, AD and related dementias cost society billions in care2. Caregivers are a critical
part of ensuring the wellbeing of AD patients as the disease progresses and are often family
members, limiting their ability to work3. The financial impact of AD currently sits at about $290
billion annually in the US, even without accounting for lost income of caregivers. This cost is
predicted to increase significantly given the baby-boomer generation is reaching the age of
dementia onset2. The growing economic burden of AD makes it critically important to
understand it in order to develop better treatments and preventative measures.

Pathologies of AD:

While the cognitive decline associated with AD is frequently the first symptom noticed
by family members or caregivers, pathological changes in the brain manifest far earlier4, 5.
Neuropathologically, diagnosis of AD requires the presence of amyloid beta (Ab) deposits as
amyloid plaques and neurofibrillary tangles composed of abnormally processed tau protein.
Both plaques and tangles are hallmarks identified by Alois Alzheimer in 19076-8. Amyloid plaques
begin to form, in some cases, decades prior to the onset of cognitive decline, while tau
pathology and tangle formation typically occurs after the plaques4, 5. Peptides of Ab and tau are
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detectable prior to cognitive decline via cerebrospinal fluid (CSF), plasma, and PET imaging
biomarkers9.
The amyloid hypothesis has dominated the AD field for decades. This hypothesis
proposes that Ab deposition is the earliest event to occur in AD, triggering the downstream
cascade of tau pathology and neurodegeneration. As a result, Ab has been of particular interest
in the field. Ab40 and 42 are products of the cleavage of the amyloid precursor protein (APP)5, 8,
9

, a transmembrane peptide that is the substrate for several enzymes including a, b, and g-

secretases. Pathological assessment of Ab deposition in autopsy is made using Thal staging. Thal
staging rages from 1 to 5, with 1 being the least severe and 5 the most. Thal staging is largely
determined by the brain regions which show Ab deposition: 1 corresponds to the neocortex; 2
corresponds to entorhinal cortex and hippocampus; 3 indicates expansion to the striatum,
hypothalamus, and forebrain; 4 requires deposition in the midbrain; and the most severe cases
at Thal 5 show plaques in the cerebellum. The first 3 stages typically are seen with pre-clinical
AD, where cognitive decline has not occurred. The final 2 stages are associated with cognitive
decline8.
Hyperphosphorylated tau neurofibrillary tangles are more closely associated with
cognitive decline than Ab deposits or amyloid plaques and occur intracellularly within neurons10,
11

. Tangle staging in neuropathology uses the Braak staging paradigm, which, like Thal,

corresponds to regional location of the tangles. Stages I-II (Roman numerals as opposed to
Arabic numbering are used for Braak staging) indicate tangles in the transentorhinal region, III-IV
corresponds to tangles in the limbic system (entorhinal and transentorhinal cortices), and V-VI
finally includes spread to the isocortical regions. Braak staging and tau deposition strongly
correlate to AD disease severity and duration7, 9, 12.
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The final staging used in assessing AD neuropathology involves the quantification of
neuritic plaques, or compact amyloid plaques containing hyperphosphorylated tau and
dystrophic neurites13, 14. This Consortium to Establish a Registry for Alzheimer’s disease (CERAD)
scoring is a measure for overall AD pathology and correlates strongly with the development of
cognitive deficits, unsurprising given the inclusion of dystrophic neurites as a criterion15.
Individual regions are assessed in CERAD staging, with each being semi-quantitatively labelled as
sparse, moderate, or frequent. Of particular interest when using CERAD staging are the superior
and middle temporal gyrus (SMTG), middle frontal gyrus, and inferior parietal lobe13, 14.

Microglia in Alzheimer’s disease:

Along with the protein aggregate pathologies described above, Dr. Alzheimer also
observed morphological changes to glial cells in diseased patients, specifically microglia and
astrocytes6. Glia, broadly, are non-neuronal cells found within the central nervous system (CNS).
These cells provide a wide variety of functions that are critical for the proper functioning of the
CNS and are subdivided based on their functions and morphologies16. The two types of glia
described by Dr. Alzheimer, astrocytes and microglia, have been studied extensively, both in
physiological and pathological paradigms. Astrocytes, while not the primary focus of this work,
are critical mediators of CNS functionality and health17. They are found in the blood brain barrier
and mediate signaling from the periphery to the CNS and vice versa17. Additionally, they are
involved in controlling neurotransmitter reuptake at the synaptic clefts between neurons17. They
also help to mediate inflammation cascades within the CNS18.
Microglia are the resident immune cells of the CNS and are vital contributors to
neuroinflammation. Secretion of cytokines by microglia can lead to both detrimental and
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beneficial inflammatory environments16, 19-23. Much of this has to do with the timing and
duration of the cytokine signaling. In the short term, microglia can properly respond to and clear
debris or foreign molecular patterns (pathogen-associated molecular patterns [PAMPs] or
danger-associated molecular patterns [DAMPs]), leading to a beneficial outcome. However,
extended durations of inflammatory signaling can cause significant off-target damage to
surrounding cells, thus causing further debris associated with cell death which then leads to
further inflammation, causing a vicious cycle of inflammation24-26.
As it pertains to AD, microglia activate in response to both Ab and tau. Under a
physiological condition a healthy response to pathology would be that the microglia surround
the pathologic aggregate and subsequently phagocytose (ingestion of larger extracellular bodies
by a cell using its plasma membrane to form a phagosome) the aggregate, which is then broken
down by sub-cellular chemical degradation of the phagocytosed proteins27, 28. Phagocytosis is a
typical process seen in other immune cells as a method for removing pathogens such as large
viruses and bacteria, and is highly evolutionarily conserved, being present in many invertebrate
species as well29, 30. However, in situations where the microglia are heavily inundated by Ab, the
microglia may senesce and die, contributing more inflammation to the local area, exacerbating
the tissue injury24.
The receptors microglia use to identify potential targets for phagocytosis are vast and
varied, but in the case of Ab deposition, NALP3, RAGE, SCARA-1, CD36, and CD14, are all
scavenger receptors that have been shown to bind to Ab25, 27, 29. Another class of receptors that
has been shown to play a role in Ab detection are the toll-like receptors (TLRs). TLRs are singlepass membrane associated proteins that bind conserved molecules derived primarily from
microbes such as bacteria or viruses31. Evolutionarily, most TLRs developed as part of a response
to infectious pathogens32. Some TLRs bind lipoproteins on the outside of bacterial cells (TLRs
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1,2,4) while others bind double-stranded RNA or unmethylated DNA, which are associated with
various viral infections (TLRs 3,7,13)27, 31-34. This shared evolutionary origin provides some
indication that TLR binding to Ab could be related to a form of response to a pathogen.
In response to TLR binding ligand, microglia will secrete pro-inflammatory cytokines in
order to recruit additional microglia via chemotaxis16, 23, 24, 26, 27. Of the myriad of proinflammatory cytokines produced under these conditions, tumor necrosis factor-a (TNFa) and
interleukin 1b (IL-1b) are two of the most well studied26, 35. Studies examining the effect of aging
on the changes in microglial signaling showed that Ab receptors decline significantly while
production of TNFa and IL-1b are significantly increased over time26. Functionally, this would
mean an increase neuroinflammation in the area, but without the benefits of the actual
clearance of the Ab. The lack of clearance and expanding neuroinflammation then contribute to
further neurodegeneration as nearby cells are damaged by the inflammatory
microenvironment.

Primary Hypotheses of Alzheimer’s disease:

While the primary pathologies associated with AD (plaques and tangles) have been the
primary focus of AD research for decades and subsequent inflammatory events have also been
studied extensively, the true underlying cause of AD is not well understood. Most of the AD field
has coalesced around either of the two primary types of protein aggregates: Ab and tau36, 37.
Given the large body of evidence involving each aggregate, there are cases to be made for and
against each aggregate as a cause of the disease.
Proponents of the appropriately named Amyloid Hypothesis believe that the formation
and accumulation of amyloid plaques is the primary driver of tangles, AD neurodegeneration,
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and ultimately cognitive decline. More specifically, the hypothesis states that AD is caused
primarily by a defect in the production, accumulation, and / or clearance of Ab, and that all
subsequent pathologies are the result of such a defect36, 37. Three main pieces of evidence are
typically used when defending this hypothesis: 1) mutations in three APP processing genes (APP,
PSEN1, and PSEN2) have been identified as causative (not merely risk-factors) of early-onset,
familial AD; 2) mouse models incorporating mutations in these genes accumulate amyloid
pathology and corroborate cognitive decline; and 3) individuals with Down syndrome (trisomy of
chromosome 21) have 3 copies of the APP gene always develop significant amyloid plaque
burden by their 40s, and 75% of individuals with Down syndrome older than 65 are diagnosed
with AD, a significantly higher proportion than the general population36-39.
The biggest complication of the Amyloid Hypothesis is the long, fruitless history of
disease-modifying drug development36, 38, 40, 41. Over two decades of anti- Ab therapies targeting
each level of Ab processing (production, cleavage, aggregation, clearance), only a single
treatment has received an accelerated FDA approval: Aducanumab42. Despite its approval,
aducanamab was not without controversy, as it was approved after post-hoc statistical
evaluation of two separate failed phase II clinical trials and still showed evidence of significant
off-target effects on brain vasculature43-45. A new, Phase III trial is mandated by the FDA to be
completed over the 2021-2026 period prior to any full approval being considered.
The other major camp in the AD field consists of those who believe that tangle
pathology and abnormal tau processing, not amyloid deposition, is the main driver of AD8, 11, 36,
40, 41

. Basically, the phosphorylation of microtubule associated protein tau (MAPT) leads to a

destabilization of microtubule assembly, which leads to synaptic dysfunction and, ultimately,
neuronal death. Evidence in support of the Tau Hypothesis is more sparse but potentially
stronger than those for amyloid. For instance, Ab can, and frequently does, exist in cases where
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no cognitive decline is observed. However, the same is not true for tau, which correlates
strongly with AD cognitive decline and severity8, 11, 36, 40, 41. Additionally, the mechanism of
neuronal death is more focused and understood than in the Amyloid Hypothesis. (i.e., Amyloid
hypothesis proposes that neuronal damage is an off-target event, while neuronal death is an
eventuality in the Tau hypothesis). Also, other forms of dementia are associated with tau, and
mutations in MAPT, including some forms of fronto-temporal dementia (FTD), progressive
supranuclear palsy (PSP), and chronic traumatic encephalopathy (CTE).
Despite a stronger tie to AD progression and cognitive progression, there are still
significant issues with the Tau hypothesis. Firstly, many other tauopathies exist and a sufficient
explanation is required for the reason why amyloid is present in only some instances of tau and
not others10, 11, 36, 38, 46. At best, it would appear that Alzheimer’s disease is, under this paradigm,
a tauopathy coincidental with amyloid aggregation. Secondly, tau interventions and clinical trials
have been just as ineffective as amyloid centric ones47. Methylene blue derivative drugs that
prevent the aggregation of tau showed promise but showed just as many concerning
methodological inconsistencies and post-hoc analyses as Aducanumab, if not more48.

Infectious Hypothesis (Early years and Dr. Ruth Itzhaki):

First proposed in 1982 by Dr. M.J. Ball in a publication by the Canadian Journal of
Neurological Sciences, the infectious hypothesis broadly suggests that microbial pathogens (e.g.,
herpesviruses initially, but has expanded to encompass other viruses and bacteria) are in some
way contributing to the development and onset of AD49. Though introduced as a theory in 1982,
evidence of significant amounts of herpes complex virus 1 (HSV1) DNA being present in the
brains of elderly individuals in 1991 was the first step in legitimizing the hypothesis50.
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A significant, though controversial, standard bearer for the infectious hypothesis has
been Dr. Ruth Itzhaki. Dr. Itzhaki’s lab has been a primary driver of the research regarding the
infectious hypothesis for decades now, though others have recently begun to earnestly join her
efforts. Through the 90’s and early 2000’s, her lab was nearly alone in publishing research on
this topic, much of it critically important in connecting various aspects of AD to herpesvirus
biomechanics and life cycles. For instance, she has shown that herpesviruses are present in the
brains of elderly individuals at a higher proportion than young individuals, that these viruses are
able to reactivate within the CNS, and that ApoE e4, the largest genetic risk factor for late-onset
AD, was a risk factor for said reactivations and severity of reactivation symptoms50-56. Her stamp
on the research in the field has proven foundational.

Infectious Hypothesis (Recent years):

High profile studies in recent years have breathed new life and attention into the
infectious hypothesis. Of particular importance have been a series of works that propose
amyloid plaques are actually the product of innate immune response to microbes in the brain.
The first of these was published in 2010 and compared Ab40 & 42 peptides (those
predominantly found in AD) against other anti-microbial peptides in terms of their ability to
prevent the growth of eight clinically relevant microbes57. This study showed that Ab42 was just
as, if not more, effective in all eight cases than LL-37, the archetypal anti-microbial protein
found in humans. Additionally, this study showed brain homogenates from AD cases showed
more anti-microbial activity than age-matched controls, though inherent inflammatory
differences due to pathology may have also accounted for this difference57. A study by the same
group in 2016 showed that amyloid plaque seeding was significantly accelerated in mouse
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models of AD when a Salmonella bacterial infection of the brain was induced58. This study also
included binding and oligomerization assays that showed the formation of Ab fibrils attached to
the exterior of the bacterium prevented adhesion to host cells and supported eventual
entrapment of the microbes58. Work in 2018 further expanded this work to show that herpes
simplex virus 1 & 2, as well as human herpesvirus 6 were bound and inhibited by Ab59. They
further showed improved survival of 5XFAD mice (an animal model of severe amyloid pathology)
compared to controls under severe herpesvirus encephalitis59. Taken together, there is strong
evidence to support the idea that Ab42 may be playing a protective role in terms of the innate
immunity of the brain, a far cry from the traditional viewpoint that Ab42 serves no purpose, or,
at the very least, an unclear one. In fact, the molecular components necessary for producing
Ab42 are highly evolutionarily conserved (as far back as bony fish), something that would not
have happened if it served no function60. In such a case, evolutionary drift would be evident, and
a lower level of conservation would be observed60.
As critical as this work was to the field in terms of suggesting how viral or microbial
infections led to the production of Ab, it did not receive a considerable amount of attention. But
in 2018, Readhead et al. was published in Neuron and brought the field into the spotlight with a
large, comprehensive analysis of three independent AD cohorts, comparing molecular, genetic,
and clinical pathways based on the presence of HHV-6 in the samples61. The study was
significant at a conceptual level since it integrated viral genomic changes with genomic,
proteomic, transcriptomic, and pathological data61. Readhead et al. showed a significant
upregulation of APP processing genes in the presence of HHV661. This was the first major study
to identify the types of gene regulations suggested by the anti-microbial Ab studies, in a
significant clinical cohort. This study has come under significant criticism in the time since, with
several groups having difficulty replicating the HHV6 quantification in the same cohorts, others
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contesting the statistical approach, and others still questioning the patient selection 62-64. Despite
that, the impact of the study was lasting. Attention returned to the field and a surge in
publications and funding opportunities has occurred in the intervening years.
Another topic of importance to this work, though not as publicly recognized, has to do
with the concept of viral reactivation in AD. I will expand on this in a following section in terms
of details, but basically, the herpesvirus family of viruses are capable of entering the nucleus
(and sometimes genome) of the host cell and becoming transcriptionally inactive, thus
preventing detection by cellular surveillance65-69. Under different conditions, the virus can
become transcriptionally active again, hijacking cellular machinery to replicate and spread65-69.
Essentially, if inactive virus is present, the virus can generate a new infectious spread under the
right conditions. Examples of this include cold sores, which are herpes simplex virus 1
reactivating, or shingles, which are varicella zoster reactivating. While those examples are
outwardly visible because of their location in the periphery, it becomes difficult to quantify the
impact of reactivations of these viruses within the brain. However, there has been work done to
examine the impact of some herpesvirus reactivation on AD progression.
A series of studies from 2015-2018 have investigated the connection between
serological markers of reactivation of herpes simplex virus 1 and the risk of AD. In 2015,
Loveheim et al. showed that the presence of anti-HSV1 immunoglobulin M (IgM), the archetypal
serological marker for viral reactivation, almost doubled the risk of AD in a large clinical cohort70.
In contrast, immunoglobulin G (IgG), which is a serological marker indicative of having had the
infection at any point, showed no effect on AD risk70. In 2016, Olsson et al. showed evidence of
HSV1 in a limited number of autopsy AD cases, showing evidence that HSV1 singularly is unlikely
to be causing AD71. This was one of a number of studies around the time suggesting a broader
number of pathogens could be driving the development of pathology. In order to expand, the

10

same group published a study in 2018 examining human cytomegalovirus (CMV) interactions
with AD and HSV172. They showed that, while CMV had no direct impact on AD risk, there was a
significant increase in AD risk when CMV and HSV1 were both present72. The authors discussed
some niche interactions in terms of one virus ‘priming’ the immune system which presents the
opportunity for the other to reactivate and expand72. Another conclusion, though, is that there
are likely underlying susceptibility factors that impact multiple members of the herpesvirus
family due to their shared biology. What these risk factors are, both for initial infection and
subsequent reactivation, is hugely important in explaining critical questions involving the
infectious hypothesis, or the anti-microbial infectious hypothesis as it has become.

Difficulties Facing the Infectious Hypothesis:

Despite promising evidence in support of the infectious hypothesis, there remain
important questions about how microbes are causing the various aspects of AD. Of major
relevance is the fact that nearly every human has been infected by a microbe that is potentially
neurotropic, but only a relatively small number eventually develop AD. This is where the risk
factors mentioned above come into play. They help to explain why every person does not
develop AD. Related to this is evidence of direct causation. There has yet to be any ‘smoking
gun’ that viruses or microbes as a whole cause AD. They may simply be coincidental. Ab is prone
to binding with many substances, so evidence that it binds to microbes may be coincidental.
Finding it in the brains of AD patients might simply be the result of infiltration via secondary
vascular damage in AD cases. Even if it is there in significant amounts prior to any kind of
damage, it’s unknown if microbes behave the same way in the CNS that they do in the
periphery. Do they reactivate in response to the same stimuli? Do they follow similar life cycles?
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There is also a significant amount of work that needs to be examined involving timing of
infection and reactivation. Does infection earlier in life have a larger impact than one later in
life? Are reactivations at certain times more impactful? How severe of a reactivation is
necessary to have an impact if it does? The concept has been likened to chronic traumatic
encephalopathy, which is a form of neurodegeneration that develops due to repeated head
trauma. In this case however, the microbes play the role of the injury, but unlike significant head
trauma, which can easily be identified in the moment it occurs, some of these microbes
asymptomatically infect and reactivate, only detectable in serological evidence when actively
monitoring for it. This makes it exponentially more difficult to longitudinally track reactivations
and infections and determine what kind of impact they are having.
Beyond that, there is very little connecting the infectious hypothesis with the tau
hypothesis. No explanations are available as to why these interactions between Ab and viruses
would cause the hyperphosphorylation of MAPT. Some studies have been performed to test if
tau tangles are the intracellular equal to Ab antimicrobial accumulation outside of the cell, but
those results have either been negative or have never been reported. In the event that the
connection is explained, it opens up questions about other tauopathies and how they relate to
viruses, and, subsequently, the reasons various pathologies do or do not occur in different
cases.
Beyond these questions, there is an existential question about why it matters whether
viruses or microbes seed amyloid plaques. If Ab is indeed anti-microbial, then AD is narrowed to
being an issue of processing the Ab properly, at least in terms of the Amyloid Hypothesis. If this
is the case, why waste time and resources trying to establish that an unpreventably unfeasible
number of microbes cause Ab deposition when those resources could be spent trying to figure
out how to fix the issue with processing? It is important to figure out exactly how the infectious

12

hypothesis can be leveraged in the curing of AD. Vaccinating or preventing against all
neurotropic infections that have been suggested as AD contributors is infeasibly large. But
identifying some underlying risk factor or mediator as being key for microbial spread in the brain
does offer the potential of preventative drug targets. At the very least, many of the factors that
contribute to viral reactivation; namely stress, general inflammation, hormonal changes and
imbalance, certain types of immune active medications; can be reduced or limited with lifestyle
intervention, as can many risk factors for vascular dementia, heart disease, and AD directly.

Human Herpesvirus 6:

Focusing more on where this work fits into the current work on the Infectious
Hypothesis, I chose to focus on HHV-6: in part because of the existing literature, but also due to
relatively high abundance within the autopsy tissue provided for this study.
HHV-6 is actually a set of two very closely related viruses: HHV-6A and HHV-6B65, 68, 73.
The prevalence of HHV-6 is nearly 100% in some communities and typically infects individuals
before the age of 3, sometimes causing fever, diarrhea, and a rash known as roseola65, 68, 73.
Importantly, this refers to their prevalence in the periphery of individuals and not necessarily
their brains. The percentage of individuals with HHV-6 in the CNS is not known, though various
studies have reported conflicting prevalence values. They are enveloped double stranded DNA
viruses. As such, they utilize the trans-Golgi network vesicles of the host cell for assembly and
virion maturation65, 68, 73. Like other herpesviruses, HHV-6’s genome contains a unique segment
with seven major cores of genes which code for various structural elements and proteins, as
well as immunomodulatory products65, 68, 73. HHV-6 binds host cells via CD46, which plays a role
in regulating the complement system. All isoforms of CD46 (14 are reported) bind HHV-665, 68, 73.
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While the exact method of entry into the cell is not well understood, it has been established that
a heterotetramer forms on the envelope of the virus to create the ligand which binds CD4665, 68,
73

.
Having CD46 as an entry receptor means that HHV-6 has a wide range of targets within

the body, with primary reservoirs being located in the salivary glands, T-cells, and olfactory
tissues65, 68, 73. In order to enter the CNS, HHV-6 can propagate through the olfactory tissue and
facial cranial nerves which provide access to the CNS via the olfactory bulb, and the pons via the
brainstem65, 68, 73. HHV-6 is capable of infecting both microglia and astrocytes due to the
presence of CD46 on both65, 68, 73. Successful replication of virus has also been observed in both
cell types65, 68, 73.
As mentioned above, HHV-6, and other herpesviruses, have a biphasic life cycle; that is,
they can be either lytic or latent within a cell65, 68, 73. When active, the genome of HHV-6 is
circularized via covalent linkages at the ends of the genome, and then expresses ‘immediate
early’ genes65, 68, 73. These genes are transcriptional regulators necessary for the expression of
‘early’ genes, which are then, in turn, needed for the expression of ‘late’ genes65, 68, 73. Most of
the genomic DNA replication related genes are encoded in the ‘early’ genes, while structural
proteins and components are found in the ‘late’ phase genes65, 68, 73. The circularized genome
results in the production of concatemers, or long repeating sequences of DNA, which are then
enzymatically cleaved in order to be packaged65, 68, 73.
When inactive, the HHV-6 genome integrates itself into the hosts DNA65, 68, 73. HHV-6 is
unique when it comes to the betaherpesviruses, or the subfamily of mammalian herpesviruses
that share a viral reservoir within leukocytes, in that it integrates into the telomeric regions of
the host DNA65, 68, 73. All other herpesviruses in this family form episomal loops within the
nucleus, akin to a bacterial plasmid65, 68, 73. A number of genes are expressed during this latent
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phase, mainly in order to suppress any active viral gene expression, maintain host cell survival,
and modulate innate immunity65, 68, 73. From this phase, the virus is capable of reactivating,
though the exact mechanisms are not well understood65, 68, 73. It is generally thought that
dramatic increases in transcription by the host cell, whatever their cause, are linked to the virus
reactivating and beginning to replicate itself65, 68, 73. Common triggers of reactivation are
emotional stress, physical damage, and hormonal imbalances65, 68, 73.

HHV6 in Alzheimer’s disease:

HHV-6 integrates into the current Infectious Hypothesis paradigm at multiple levels.
Firstly, as a virus capable of entering and infecting the CNS, it is capable of seeding plaques55.
Essentially, HHV-6 fits the role of a potential pathogenic invader being ensheathed by Ab and
then eliminated by microglia under normal conditions, with AD being a failure to clear these
plaques effectively. It is important to note that HHV-6 is not only able to enter via
olfactory/facial cranial routes, but also via T-cells. This could occur in the case of vascular injury,
which fits within the high co-morbidity of vascular disease and AD, or recruitment by the CNS via
chemotaxis, which suggests the possibility of a compounding response to a viral infection in the
CNS (i.e., Virus is ensheathed, microglia come to deal with Ab, microglial cytokines lead to
recruitment of T-cells, T-cells are infected with HHV-6, HHV-6 replicates from the T-cell, more
Ab)74, 75.
HHV-6’s immunoregulation also potentially might play a role in the development of AD,
especially given its tropism for microglia and T-cells76. Basically, if microglia attempting to
resolve an Ab plaque have latent HHV-6 present, the immunoregulation caused by the latent
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genes expressed might impair function of those cells, preventing processing of the Ab, leading
to the sustained inflammation that has been identified as particularly detrimental to the health
of the brain76. HHV-6’s tropism for these cells might help explain why damage is so slow to
accumulate and progress, as opposed to more neurotropic viruses, which infect neurons,
leading neuronal death which would likely be more noticeable and damaging.

Apolipoprotein E as it Pertains to the Infectious Hypothesis:

Apolipoprotein E (ApoE) was mentioned above in the context of its e4 isoform: the
largest genetic risk factor for AD77, 78. ApoE e3 is the most commonly occurring isoform (~78% of
the population). In contrast, e4 is present in just 14% of the population, but around 37% of AD
patients. Individuals homozygous for e4 are at almost 15x the risk of developing AD compared to
homozygous e3 individuals79, 80.. e2, on the other hand, has been shown to be protective against
AD, but is the rarest of the three common isoforms (9% overall, 5% of AD cases). ApoE is the
primary lipid and cholesterol transporter in the brain79, 80. It is mainly generated by astrocytes,
though can be produced by microglia and neurons under stress79, 80. Its main function is to clear
lipoproteins from the low-density lipoprotein receptor (LDLR) 79, 80. The different isoforms (e2,
e3, & e4) found in humans have different affinities for binding the lipids being transported and
LDLR79-81. The e4 isoform has low affinity for both the lipids and the receptor, meaning
ineffective transport of important lipids to cells which need them for proper functioning82, 83. In
addition, the e4 isoform is responsible for impaired recycling of several other receptors and
proteins, including APP itself84, 85. This impairment of APP recycling is thought to lead to the
production of excess Ab84, 85. On a general level, the e4 isoform has a significant effect on the
trafficking of various receptors and vesicles: key components of viral life cycles84, 85.
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While a direct link has yet to be drawn between ApoE e4 and the biomechanics of viral
entry or vesicular transport, there is significant evidence that ApoE e4 is a risk factor for CNS
infection by multiple viruses, as well as for reactivation of various viruses. Studies as early as
2002 showed that ApoE contributed to the migration of HSV1 into the CNS, and further, that the
e4 isoform resulted in more efficient transport into the brain86, 87. This was further supported by
findings that e4 carriers had greater amounts of latent HSV1 present in their brains than
individuals without e488, 89. Additionally, studies have shown that e4 was more permissive to the
establishment of viral latency and subsequent reactivation54, 90-95. Taken together, there is strong
evidence to suggest ApoE e4 is a significant risk factor as it pertains to the any potential
interaction between HHV-6 and the development of AD.

Hypothesis:

This work aims to assess the role of HHV-6 reactivation on the progression of AD and
associated cognitive decline. First, I hypothesized that individuals suffering from more frequent
reactivation of HHV-6 would experience more rapid cognitive decline and be more likely to
develop AD. Second, I hypothesized that latent HHV-6 infection of microglia would result in
reduction of inflammatory signaling and phagocytic capacity in an ApoE e4 dependent manner
(i.e., e4 occurs with lower inflammation in HHV6 infected AD cases and lower phagocytic
capacity).
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CHAPTER 2: Investigating the Relationship Between HHV-6 Reactivation and Cognitive Decline &
Alzheimer’s Disease Pathology
Introduction:

The scientific debate regarding a possible infectious etiology of Alzheimer’s disease (AD)
has grown in recent years with multiple high-profile studies being published both in support of
and against. Of the many pathogens suggested, the herpesvirus family represents one of the
longest studied and most ubiquitous of the potential perpetrators55, 63, 74, 96. Evidence of
herpesvirus genomic DNA being extracted from plaques has been reported as early as 199150.
Controversial studies by Eimer et al. and Readhead et al. have suggested, respectively, a role for
amyloid beta as an anti-microbial peptide, and HHV6 as a potential driver of inflammatory gene
expression changes seen in AD59, 61. Even outside the controversy of AD and the central nervous
system, evidence of HHV6 involvement in the development of multiple sclerosis, a degenerative
peripheral nervous system disorder, has been shown97. Evidence suggests that HHV6 molecular
mimicry contributes to the development of auto-immune function against the neurons
themselves. In the case of amyloid and AD, a similar immune response could be caused within
the CNS by the virus, leading to the aggregation of amyloid rather than the direct auto-immune
damage to the neurons. A chief argument against many of the studies in support of the
infectious hypothesis is that there is no explanation for why ubiquitous pathogens are causing
neurodegeneration in a small subsection of the population64. One of the suggested explanations
is that there are underlying differences predisposing certain people to more frequent
reactivation of herpesviruses, thereby creating a difference in pathogen/immune interactions
within the nominally ‘positive’ disease group98-101.
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While it has been hypothesized that reactivation of herpesviruses could be contributing
to cognitive decline and AD, it remains a relatively understudied field. Lovheim et al. showed
evidence of herpes simplex reactivation being predictive of eventual AD diagnosis70. Serology
evidence in other studies has also shown that IgM immunoglobulins against various
herpesviruses were correlated with worse cognitive decline and neurodegenerative
pathologies72, 93, 97, 102. While these studies support the hypothesis of reactivation, one of the
difficulties in examining reactivation of herpesviruses is the relatively large amount of
unobservable time. Infections with many of these viruses occur in infancy or adolescence, well
before any type of inclusion in longitudinal clinical studies examining aging and cognitive
decline. In addition, there remains no way to identify the overall number or frequency of
reactivations in a person’s lifetime without actively testing for viral infections routinely, which is
costly and invasive. Importantly, differences in reactivation have been observed based on age
and apolipoprotein E genotype; the largest genetic risk factor for AD52, 54, 86, 88, 89, 94, 103. While
studies examining the effect of reactivation of specific herpesviruses, such as HHV6, on cognitive
decline and AD are few and far between, a study by Kobayashi et al. from 2019 showed
evidence that overall antibody titers against HHV6 were negatively correlated with age, which
they interpret as an attenuation of reactivation of HHV6 with age, though global antibody titers
are known to decline with age and offers a more plausible explanation of their results104. Beyond
this study little has been examined regarding HHV6 reactivation in aging AD populations.
In order to add to the overall body of evidence, we screened subsets of the SandersBrown Center on Aging population for 1) self-reported evidence of herpesvirus reactivations, 2)
serological evidence of HHV6 infection and reactivation, and 3) presence of HHV6 in postmortem brain tissue. Once collected, these data were then used to compare relative cognitive
decline in these patients over time, as measured via neuropsychiatric testing. Neuropathology
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was also compared using the post-mortem results. Finally, neuroinflammatory gene expression
was assessed in the post-mortem tissue in order to identify any alterations concomitant with
the presence of HHV6.

Methods and Reagents:

Sample Collection:
All post-mortem tissue, plasma samples, and neuropsychiatric testing data were provided by the
Sanders-Brown Center on Aging Neuropathology Core, Biomarker Core, and Clinical Core,
respectively. Participants in this study were selected from the University of Kentucky
Alzheimer’s Disease Research Center (UK-ADRC) cohort. The characteristics and demographics
of the UK-ADRC cohort has been previously described105. All participants provided written and
informed consent for their participation in the UK-ADRC research. All the research herein has
been approved by the University of Kentucky Institutional Review Board. Neuropathological
scores (Braak & CERAD) were acquired for all post-mortem tissue used.

Survey:
Surveys were formulated in consultation with the Sanders-Brown Neuropsychology and Clinical
Cores. A total of 462 patients responded to the survey. A copy of the surveys can be found
attached (Supp. Fig 1). All data was collected from returned surveys by blinded researchers and
added to the Sanders-Brown Center on Aging data core for long term reference. This study was
approved by the University of Kentucky Institutional Review Board.
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ELISAs:
Anti-HHV6 IgG and IgM ELISAs (Creative Diagnostics: Anti-HHV-6 IgG (DEIA3565) & IgM
(DEIABL57)) were used to assess semi-quantitative levels of each immunoglobulin in longitudinal
plasma samples (n=45 patients w/ a range of 2-6 samples per patient) according to
manufacturer’s protocol. Plasma samples were diluted 1:50 in their proprietary dilution buffer
according to manufacturer instructions. Plates were read using a ThermoFisher MutiskanFC at a
wavelength of 450nm. Results were analyzed according to the manufacturer’s semi-quantitative
protocol rather than quantitative due to the variable freeze-thaw counts amongst the plasma
samples that may lead to differences in viability.

RNA Extraction:
Frozen autopsy superior medial temporal gyrus and cerebellum tissue was extracted for RNA as
previously described106. Briefly, tissue was flash frozen with liquid nitrogen, homogenized via
mortar and pestle, and subsequent rotor homogenization and then RNA was extracted using the
E.Z.N.A. Total RNA Kit according to manufacturer’s instructions. Aliquots of the RNA were sent
to the UK College of Medicine Genomics Core for concentration and RNA integrity
determination using an Agilent 2100 Bioanalyzer.

cDNA Preparation:
RNA from each of the selected regions was also used to generate cDNA as previously
described107. Briefly, the High Capacity cDNA Kit (ThermoFisher, Grand Island, NY) was used to
generate cDNA at a concentration of 50ng/µL and then stored at -20°C in preparation for RTqPCR. The cDNA was used in ddPCR to assess which viral genes were actively being expressed, in
order to determine whether virus present was reactivating.

21

Genomic DNA Extraction and Restriction Enzyme:
Pulverized tissue from each brain region selected had genomic DNA extracted from it using the
DNAzol Reagent (Invitrogen: 10503027) and then 500µl of extracted DNA was treated with
HinDIII (ThermoFisher: ER0501) according to manufacturer’s instructions. Digested DNA was
then used for ddPCR to assess the presence of viral genes, both latent and reactive.

Droplet Digital PCR:
Genomic DNA from previous steps were diluted to a concentration of 50ng/µL to match
cDNA concentrations. AAMP was used as the endogenous control (ThermoFisher: 4331182)
while U22, a viral glycoprotein expressed only during the late phase of viral gene expression,
was used to assess viral presence, and was ordered from Creative Diagnostics according to
descriptions as previously described108. Given this, the gene should only be expressed in the
cDNA samples if the virus was actively replicating at the time of fixation. Both cDNA and gDNA
samples were loaded into droplet formation solution according to manufacturer directions and
subsequently underwent droplet partitioning. Samples then underwent manufacturer
recommend thermocycling amplification before being evaluated via BioRad Plate Reader.
Thresholds were then set according to standards in Allnut et al63. Samples were then assessed
for positive amplification in a significant number of droplets. Ancillary experiments seemed to
indicate relatively low integrity of samples, preventing full leveraging of the ddPCR technology
for quantification.
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NanoString:
Aliquots of 10µL of 10ng/µL RNA were prepared and run by the UK College of Medicine
Genomics core on the NanoString SPRINT system using the NanoString Human
Neuroinflammatory Panel kit containing 770 genes of interest. Gene expression for all
endogenous genes was investigated using multivariable linear regression models (Gene
Expression Data Analysis Guidelines, NanoString Technologies, 2017). Transcript counts for each
gene were regressed on the sum of all positive control gene counts (for normalization), and an
indicator for: presence of virus (yes or no), genotype (e3 or e4), or sex (male or female). Gene
expression counts were log-transformed (base 2) to normalize the data prior to modeling
(nCounter Advanced Analysis 2.0 Plugin for nSolver Software, NanoString Technologies, 2018).
The differential expression p-values for viral status, genotype, and sex were adjusted using an
FDR cutoff of 0.05 and converted to q-values. Benjamini-Hochberg correction for false discovery
rate was applied to these values with values with a q-value less than 0.05 being considered
significant. All analyses were performed in R version 4.0.3 (R Core Team (2020), Vienna, Austria).
Significantly differentially regulated genes are listed individually in Supplemental Tables
1-3. Genes were grouped based on NanoString’s functional descriptors of the panel and then
graphed with both up and downregulated genes for each functional group on the same axis.
Cognitive Domains:
Verbal memory, verbal fluency, language, attention, executive function, processing
speed, total function, and global cognition were evaluated approximately annually in each
patient starting at admission to the cohort. Cognitive domain scores were calculated for each
individual by taking age, sex, and education adjusted z-score of the tests making up each domain
and averaging them. Raw scores from the cognitive assessments were converted using the
National Alzheimer’s Coordinating Center (NACC) z-score calculator109. Briefly, the NACC collects
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data from numerous AD clinical populations and each patient’s score for a given cognitive
domain was subtracted from the NACC population average, then divided by the NACC
population standard deviation. Evaluations completed before 2015 were performed using UDS2
guidelines, while those completed after that date were performed using UDS3 guidelines.
Cognitive tests performed only in UDS3 were converted to raw scores of their UDS2 counterpart
using the NACC crosswalk before then calculating z-scores as described110. These z-scores were
then plotted over the course of the patients’ recorded visits and the line of best fit was plotted.
The slope of this line was then used as the rate of cognitive change in that domain for each
patient.

Statistics:
Normality of each data set was assessed via the Shapiro-Wilks test for normality using
JMP. Data for the cognitive domain analyses were fit to generalized linear models to assess their
relationship with the rates of cognitive decline. Parameter estimates, upper and lower 95%
confidence intervals, and the standard error are reported for each model. Summary statistics for
each group of cases used can be found in Tables 1, 3 and 6.
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Results:

Self-Reported Measures Indicate That Markers of Herpesvirus Reactivation Do Not Influence
Rates of Cognitive Decline:
Self-reported indicators of herpesvirus reactivation showed no statistically significant
relationships with the rate of decline in most any of the measured cognitive domains, however
for verbal memory, there was an improvement in cognitive rate of decline in patients who did
not have shingles (Shingles is the colloquial term for a painful reactivation of the varicella zoster
virus) (Table 2h). All other significant variables are expected variables related to AD progression,
such as age, sex, years of education, ApoE e4 allele presence, and baseline cognitive
assessments (Table 2).
Stress response questionnaire responses is believed to be confounded by the ongoing
COVID-19 pandemic, making it difficult to assess any connections between generalized stress, a
known trigger of herpesvirus reactivation, and any of the self-reported measures. Dental or
facial surgeries, which may cause incidental damage to the facial cranial nerves triggering
reactivation of HSV-1 latent there, showed no relationship with the self-reported measures.

Serological Markers of HHV-6 Reactivation Did Not Correlate With Significantly Worsened
Cognitive Decline:
IgG screening of patient plasma samples showed a significant relationship with a
cognitive domain; anti-HHV-6 IgG positivity weakly correlated with an improvement in language
performance over time (Table 4d). The effect, though significant, is very small and would seem
to indicate very little effect of anti-HHV6 carriage on cognitive decline. Any other significant
relationships were associated with the variables mentioned above (Table 4).

25

Upon screening the same samples for anti-HHV6 IgM, a marker for reactivation of the
virus, we found no significant relationships involving IgM positivity (Table 5). All significant
relationships observed were with expected AD variables such as age, sex, years of education,
ApoE e4 allele presence, and baseline cognitive assessments.

Evidence of Latent HHV-6 in Autopsy Tissue Did Not Show Any Effect on Cognitive Decline or
Neuropathological Severity:
The only significant relationship observed based on the presence of HHV6 in autopsy
tissue was a positive association between the presence of latent virus and processing speed
(Table 7e). No other significant relationships were observed in other cognitive domains (Table
7). Some significant relationships were observed in terms of neuropathology that recapitulate
expected AD neuropathological associations. Braak scoring had a significant positive relationship
with age, which is to be expected in an AD cohort (Table 8a). CERAD staging showed a similar
relationship with age as well, while also having a significant relationship with sex (Table 8b).
Female cases were associated with lower levels of neuritic plaques denoted by CERAD staging.
Differential Expression of Inflammatory Genes Indicate Significant Modulation of Microglial,
Cytokine, and T-cell Related Functional Gene Groups:
NanoString analysis of the superior medial temporal gyrus and cerebellum in HHV6
positive and negative samples showed a significant correlation between the presence of HHV6
and several inflammatory related genes, such as RELA, TNFa, IL1b, and multiple toll-like
receptors, as well as genes indicative of the recruitment and presence of T-cells from the
periphery (Supp. Tables 1-3). Additionally, modulation of microglial markers and function
indicate some effect of HHV6 on microglia (Figure 1).
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Discussion:
This study investigated the connection between HHV6 reactivation, cognitive decline,
and eventual diagnosis on three distinct levels. At the patient self-report level, we saw a
significant relationship between a lack of shingles and positive cognitive progression (i.e. A
slower decline or lack of change relative to the population’s average decline for the same time)
in verbal memory. It is important to note that shingles vaccine use was not collected in this
survey and may have accounted for the large number of individuals who had not had shingles.
Previous research has shown a connection between shingles vaccine use and AD risk, specifically
that vaccination reduced the risk of AD, as well as other viruses and their respective vaccines52,
111, 112

. Shingles, or varicella zoster reactivation, is highly inflammatory response that triggers a

significant immune response in the periphery113, 114. This peripheral inflammation may
contribute to cognitive decline via damage along the vasculature. Heightened inflammation
could be causing damage to the blood brain barrier, causing subsequent dysregulation of
astrocytes and associated neurons leading to cognitive decline and effects. This mechanism is
independent of AD, but may occur synergistically or even potentially contribute to AD-related
inflammation. These findings do suggest that further investigation of zoster, and other
neurotropic herpesviruses, as potentiators of disease is merited.
The asymptomatic nature of HHV6’s reactivation makes it difficult to assess
independently (See Methods). However, the general triggers of reactivation in most common
herpesviruses are similar enough that examining hallmarks of other reactivations can provide a
rough shewn picture of HHV6’s potential reactivations55, 65-68, 96, 101. In an ideal situation, more
frequent serological sampling over a longer time frame would give more detailed information
about the frequency and duration of HHV-6 reactivation specifically. This approach also requires
the assumption that peripheral reactivation of HHV-6, as measured by IgM flux, is comparable to
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reactivation in the CNS, which we can only measure via post-mortem PCR amplification of viral
genetic material from brain tissue. However, there are no current alternatives that would allow
measuring HHV-6 reactivation in vivo without significant invasive procedures.
At the serological level, we saw no relationship between either anti-HHV6 IgG or IgM
and cognitive decline of a sizeable effect, indicating no influence on clinical progression of
cognitive decline in any domain. The small effect change attributed to IgG carriage and language
is minimal and could be the result of sampling a small selection of patients. Previous studies
reported similar results from another herpesvirus: cytomegalovirus(CMV)72. However, in that
study, they did observe a synergistic effect on AD risk when both anti-HSV1 and anti-CMV IgM
were present in high levels72. A similar effect could exist with HHV-6, a secondary virus, like HSV1, being necessary to drive a clinically relevant outcome. In that case, one virus is likely to alter
host immunity in such a way that increases the spread or virulence of the second virus. In this
case, HHV-6 may be altering microglia or T-cell function in such a way to allow HSV-1 to replicate
and spread more readily, leading to stronger impact on AD pathology.
At the ddPCR level, our results conflict with the existing literature to an extent. Allnut et
al. showed a remarkably low level of HHV6 in autopsy tissue from two independent Alzhiemer’s
disease cohorts, however we observed almost 50% of our cases having HHV6 present in their
brains63. We followed the protocols set out in Allnut et al. yet observed dramatically different
results. However, our cohort is distinct from those examined in their study; prevalence of
herpesviruses does fluctuate along socioeconomic levels and regional differences65, 115, 116. It is
possible that the environment and less urban population of the UK-ADRC cohort makes it more
likely to have HHV6. Additionally, there may be additional factors, such as higher incidence of
cancers, smoking, heart disease, diabetes, or drug use; contributing to higher reactivation within
our cohort, leading to greater possible spread and eventual entry into the CNS. It is important to
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note that the population examined in this study excluded patients with cancer. Smoking status
and drug use were not ascertained. Expanding future studies to gauge the impact of these risk
factors in the context of HHV-6 may help to explain differences observed.
Despite the high prevalence of HHV6, we did not observe a significant relationship
between HHV6 presence and diagnosis or cognitive decline, except for a positive relationship
between latent HHV6 and processing speed. This was a confusing result as it implies that
processing speed performance improves with the presence of latent HHV-6, which opposes the
hypothesis that the presence of HHV-6 would negatively affect cognition. There’s also a
possibility of a competitive interaction occurring within the regions specific to processing speed.
HHV-6 might be out competing a different pathogen that damages those regions directly,
though this suggests a mutually beneficial relationship between HHV-6 and the brain, which
seems unlikely given its interactions elsewhere in the body and even in the brain62, 63, 73, 75, 96, 104,
116

.
Gene expression, assessed via NanoString, revealed two notable trends. First, the

upregulation of inflammatory genes including members of the NFkb signaling cascade. This is
not a surprising finding for several reasons. First, this is autopsy tissue which, despite
consistently low post-mortem intervals, has undergone some duration of hypoxia and
subsequent cell damage and death. Still, all cases examined are post-mortem, so something
additional is accounting for the differences between the groups. Second, the presence of a virus
should trigger canonical inflammatory pathways in the brain20, 74, 117-119. We are curious if any of
the identified changes are present prior to infection and/or death and might contribute to
susceptibility to HHV6 entry or reactivation. Abnormally high levels of different cytokines may
contribute to peripheral T-cell recruitment, which would then open the possibility of T-cells
carrying latent HHV6 into the brain. Incidentally, we observed evidence of T-cell recruitment and
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presence into the temporal region. This opens a proverbial chicken-or-the-egg question: is the
HHV6 present entering the brain via T-cells responding to recruitment signals related to
neuropathology or is the HHV6 entering independently of the T-cells and contributing to the
neuropathology which then leads to the entry of the T-cells. We aim to examine the potential
different scenarios in future studies.
The fact that we see very few cognitive changes, but considerable differences in terms
of inflammatory gene differential expression seems to fly in the face of substantial connections
between inflammatory cascades and cognitive decline. However, it is important to note that our
specific measure of cognitive progression may have oversimplified the intricacies of cognitive
decline. By including all time points of cognitive assessment and using a line of best fit, we
disregard the differences in progression from year to year (i.e. The shape of the cognitive
change as a function of time of each patient is not accounted for.) As such, our cognitive
measures are likely more homogenous than in other studies, leading to difficulties in finding
significant relationships. However, the NanoString findings not only corroborate previous
literature on relationships between inflammatory gene changes and cognitive decline, but it also
aligns with what we would expect to observe in the case of a viral infection (e.g. Significant
changes in cell survival, innate immune, and cytokine genes.)
Overall, this study adds to the body of evidence in the ongoing debate about the
potential role of HHV6 in the progression of AD. We show that serological markers of HHV-6
reactivation exert little to no influence on the rate of cognitive decline or eventual
neuropathological severity. We found that incidence of shingles was negatively correlated with
verbal memory progression. Further, the presence of latent HHV-6 populations in the brains of
autopsy cases was not correlated with worsened cognitive decline. Additionally, we see
evidence that mere carriage of HHV-6 is insufficient to contribute to disease. Our gene
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expression findings present new mechanistic directions to examine the sequence of pathological
changes in relation to the recruitment of peripheral T-cells, as well as the role of resident
mediators of inflammation within the brain.
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Table 1: Summary Statistics for Patient Survey
Mean (Standard Deviation)
Age
78.1 (7.5)
Years of Education
16.52 (2.7)
% of cases (n)
E4 Allele Present
29.44 (136)
Sex = F
63.00 (269)
Chicken Pox = Yes
83.92 (355)
Shingles = Yes
25.98 (106)
Orofacial Surgery = Yes
80.95 (374)
Anti-herpetic use = Never
77.27 (357)
Summary statistics for self-report measures. Age and education are presented as population
mean and standard deviation. The rest of the variables are presented as a percentage of the
total cases and the total number of cases that have that criterion.
Table 2a: Generalized Linear Model of Self-Report Variables on Attention
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.122569

0.132

-0.426282

0.0560735

Chicken Pox [No]
Baseline MMSE zscores

0.0039149 0.016302

0.8104

-0.028163

0.0359923

0.0152415 0.005725

0.0082*

0.0039773 0.0265057

Sex [Female]

0.0046269 0.010644

0.6641

-0.016318

0.0255714

-0.011118

0.01463

0.4479

-0.039906

0.0176698

Years of Education

0.0029705 0.003843

0.4401

-0.004591

0.0105316

Age

0.0012663 0.001321

0.3385

-0.001333

0.0038657

Orofacial Surgery [No] -0.020049 0.01413
OTC Usage [3 or fewer
times]
-0.035224 0.02023
OTC Usage [4 or more
times]
0.0194583 0.024886

0.1569

-0.047853

0.0077544

0.0826

-0.07503

0.0045814

0.4349

-0.029511

0.0684271

E4 [N]

-0.185104

Shingles [No]
-0.013333 0.010502 0.2052 -0.033999 0.0073325
OTC Usage [3 or fewer
times]*E4 [N]
0.012081 0.019932 0.5449 -0.027139 0.0513015
OTC Usage[4 or more
times]*E4 [N]
-0.002487 0.024548 0.9194 -0.050791 0.0458166
Outcome variables of the generalized linear model of self-report variables on the Attention
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 2b: Generalized Linear Model of Self-Report Variables on Executive Function
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%

Intercept
-0.479117 0.226992 0.0356* -0.925834 -0.032399
Chicken Pox [No]
0.026073
0.03084 0.3985 -0.034619 0.0867648
Baseline MMSE zscores
0.0088404 0.012254 0.4712 -0.015276 0.0329566
Sex [Female]
0.0508451 0.019972 0.0114* 0.0115408 0.0901494
E4 [N]
-0.064643 0.028598 0.0245* -0.120923 -0.008362
Years of Education
-0.000444 0.007266 0.9513 -0.014745 0.0138558
Age
0.0072501 0.002526 0.0044* 0.0022789 0.0122213
Orofacial Surgery [No] 0.0254215 0.026765 0.343
-0.027252 0.0780955
OTC Usage [3 or
fewer times]
0.0079549 0.038191 0.8351 -0.067205 0.0831148
OTC Usage [4 or more
times]
-0.02641 0.048415 0.5858
-0.12169 0.0688702
Shingles [No]
0.0168471 0.019699 0.3931 -0.021921 0.055615
OTC Usage [3 or
fewer times]*E4 [N]
0.0638631 0.037925 0.0932 -0.010772 0.1384979
OTC Usage[4 or more
times]*E4 [N]
-0.070051 0.048599 0.1505 -0.165692 0.0255902
Outcome variables of the generalized linear model of self-report variables on the Executive
Function cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter antiherpetic. E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 2c: Generalized Linear Model of Self-Report Variables on Global Cognition
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.2659482 0.175874

0.1316

-0.080164

0.6120604

Chicken Pox [No]
Baseline MMSE zscores

-0.043289

0.023787

0.0698

-0.090102

0.0035234

-0.03905

0.01365

0.0045*

-0.065913

-0.012187

Sex [Female]

0.013832

0.016066

0.39

-0.017786

0.04545

E4 [N]

0.0504388 0.021565

0.0200*

0.0080005 0.0928771

Years of Education

0.0010369 0.005596

0.8531

-0.009976

0.0120494

Age

-0.00395

0.001887

0.0371*

-0.007663

-0.000237

Orofacial Surgery [No]
OTC Usage [3 or fewer
times]
OTC Usage [4 or more
times]

-0.02969

0.021002

0.1585

-0.071021

0.0116422

-0.006964

0.029047

0.8107

-0.064127

0.0501996

0.0380399 0.036685

0.3006

-0.034155

0.1102345

Shingles [No]
-0.004297 0.015042 0.7754 -0.033899 0.025306
OTC Usage [3 or fewer
times]*E4 [N]
0.0474985 0.028848 0.1007 -0.009274 0.1042707
OTC Usage[4 or more
times]*E4 [N]
-0.007938 0.036691 0.8289 -0.080145 0.0642688
Outcome variables of the generalized linear model of self-report variables on Global Cognition.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.
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Table 2d: Generalized Linear Model of Self-Report Variables on Language
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.0002308 0.088634

0.9979

-0.17419

0.1746515

-0.017983

0.012118

0.1389

-0.041829

0.0058638

0.0126027 0.005099

0.0140*

0.0025683 0.0226372

Sex [Female]

-0.005261

0.007862

0.5039

-0.020732

0.0102108

E4 [N]

0.0099797

0.01064

0.349

-0.010959

0.0309186

0.0030281 0.002751

0.2719

-0.002386

0.0084418

-0.000958

0.000954

0.3162

-0.002837

0.0009201

0.0041154 0.010408

0.6928

-0.016366

0.0245972

-0.007017

0.014517

0.6292

-0.035584

0.0215505

-0.006783

0.017999

0.7066

-0.042202

0.0286363

Chicken Pox [No]
Baseline MMSE zscores

Years of Education
Age
Orofacial Surgery [No]
OTC Usage [3 or fewer
times]
OTC Usage [4 or more
times]

Shingles [No]
-0.003282 0.007629 0.6674 -0.018294 0.0117304
OTC Usage [3 or fewer
times]*E4 [N]
-0.011347 0.014413 0.4317
-0.03971 0.0170152
OTC Usage[4 or more
times]*E4 [N]
0.0174232 0.017878 0.3306 -0.017759 0.0526056
Outcome variables of the generalized linear model of self-report variables on the Language
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 2e: Generalized Linear Model of Self-Report Variables on Processing Speed
Term

Estimate

Std Error

Prob>|t|

Lower
95%

Upper
95%

Intercept

-0.272039

0.127054

0.0331*

0.522076

-0.022001

Chicken Pox [No]

-0.012816

0.017282

0.4589

0.046827 0.0211948

Baseline MMSE zscores

-0.00328

0.007391

0.6575

0.017825 0.0112653

0.0023823 0.011197

0.8317

0.019652

0.024417

-0.031547

0.015656

0.0448*

0.062357

-0.000736

Years of Education

0.0063016 0.004006

0.1168

0.001583 0.0141861

Age

0.0022951 0.001413

0.1054

0.000486 0.0050758

Orofacial Surgery [No]

0.0087368

0.01507

0.5625

-0.02092

OTC Usage [3 or fewer
times]

-0.000188

0.021166

0.9929

0.041842 0.0414661

OTC Usage [4 or more
times]

0.0314635 0.026915

0.2433

0.021504 0.0844311

0.0067461 0.010986

0.5397

0.014875 0.0283667

-0.004208

0.8411

0.045487 0.0370705

Sex [Female]
E4 [N]

Shingles [No]
OTC Usage [3 or fewer
times]*E4 [N]

0.020975

0.0383935

OTC Usage[4 or more
times]*E4 [N]
-0.018257 0.026665 0.4941 0.070733 0.0342187
Outcome variables of the generalized linear model of self-report variables on the Processing
Speed cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter antiherpetic. E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 2f: Generalized Linear Model of Self-Report Variables on Total Function
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

-0.043816

0.063672

0.4919

-0.169127

0.0814941

Chicken Pox [No]
Baseline MMSE zscores

-0.006966

0.008723

0.4252

-0.024133

0.0102018

0.0130206 0.003716

0.0005*

0.0057079 0.0203334

Sex [Female]

0.0050625 0.005685

0.374

-0.006127

0.0162519

E4 [N]

0.0004633 0.008137

0.9546

-0.015551

0.0164781

Years of Education

0.0027721 0.002014

0.1696

-0.001191

0.0067348

Age

0.0000851 0.000697

0.9029

-0.001287

0.0014572

Orofacial Surgery [No] -0.009262 0.007557
OTC Usage [3 or
fewer times]
-0.003439 0.010784
OTC Usage [4 or more
times]
0.0242835 0.014004

0.2213

-0.024135

0.0056105

0.75

-0.024663

0.0177854

0.084

-0.003277

0.0518444

Shingles [No]
-4.169e-5 0.005496 0.994
-0.010858 0.0107747
OTC Usage [3 or
fewer times]*E4 [N]
0.0169823 0.010736 0.1148 -0.004147 0.0381112
OTC Usage[4 or more
times]*E4 [N]
-0.003578 0.014061 0.7993 -0.031252 0.0240951
Outcome variables of the generalized linear model of self-report variables on the Attention
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 2g: Generalized Linear Model of Self-Report Variables on Verbal Fluency
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.0413302 0.132443

-0.219281

0.3019411
0.0281051

Chicken Pox [No]
Baseline MMSE zscores

0.017683

0.7054

-0.041486

0.0148103 0.006637

0.0264*

0.0017503 0.0278703

Sex [Female]

0.0001369 0.011535

0.9905

-0.022562

0.0228354

E4 [N]

0.0092689

0.01573

0.5561

-0.021683

0.0402208

Years of Education

0.00149

0.004148

0.7197

-0.006672

0.0096523

Age

-0.001351

0.001439

0.3486

-0.004181

0.0014801

0.0120482 0.015325

0.4324

-0.018107

0.0422038

0.021848

0.7043

-0.051291

0.0346921

0.0032943 0.026604

0.9015

-0.049055

0.0556438

Orofacial Surgery [No]
OTC Usage [3 or fewer
times]
OTC Usage [4 or more
times]

-0.00669

0.7552

-0.0083

Shingles [No]
0.0116927 0.011388 0.3053 -0.010715 0.0341004
OTC Usage [3 or fewer
times]*E4 [N]
-0.016095 0.021603 0.4568 -0.058604 0.0264146
OTC Usage[4 or more
times]*E4 [N]
0.0015759 0.026263 0.9522 -0.050103 0.0532545
Outcome variables of the generalized linear model of self-report variables on the Attention
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 2h: Generalized Linear Model of Self-Report Variables on Verbal Memory
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.1880833 0.163311

0.2504

-0.133298

0.5094642

Chicken Pox [No]
Baseline MMSE zscores

-0.028847

0.021786

0.1865

-0.071719

0.0140254

0.017602

0.007802

0.0248*

0.0022492 0.0329549

Sex [Female]

-0.008442

0.014488

0.5605

-0.036953

0.0509852 0.019639

0.0099*

0.0123368 0.0896335

Years of Education

-0.002956

0.005107

0.5632

-0.013006

0.0070946

Age

-0.001756

0.001781

0.3249

-0.00526

0.0017482

Orofacial Surgery [No]
OTC Usage [3 or fewer
times]
OTC Usage [4 or more
times]

-0.005432

0.019035

0.7755

-0.042892

0.0320271

0.003313

0.027379

0.9038

-0.050566

0.0571922

0.0501057 0.033293

0.1334

-0.015412

0.1156232

E4 [N]

0.0200687

Shingles [No]
0.028684 0.013968 0.0409* 0.0011971 0.056171
OTC Usage [3 or fewer
times]*E4 [N]
-0.007651 0.027055 0.7775 -0.060894 0.0455916
OTC Usage[4 or more
times]*E4 [N]
0.0332845 0.03285 0.3118
-0.03136 0.0979294
Outcome variables of the generalized linear model of self-report variables on the Attention
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 3: Summary Statistics for Serology
Mean (Standard Deviation)
Median Age
78.9 (6.8)
Years of Education
16.3 (3.0)
% of cases (n)
E4 Allele Present
46.67 (21)
Sex = F
53.33 (24)
Summary statistics for serology measures. Age and education are presented as population mean
and standard deviation. The rest of the variables are presented as a percentage of the total
cases and the total number of cases that have that criterion.

Table 4a: Generalized Linear Model of Anti-HHV6 IgG on Attention
Lower
Term
Estimate Std Error Prob>|t|
95%
-0.157448

Upper
95%

Intercept
Baseline MMSE zscore

0.366058

0.6697

-0.899848

0.5849519

0.0132726 0.011528

0.2572

-0.010107

0.0366522

IgG %+ Samples

0.0005975 0.000634

0.3524

-0.000689

0.0018837

E4 [N]

0.0297514 0.024133

0.2256

-0.019193

0.0786954

Sex [Female]

-0.022545

0.02553

0.3831

-0.074323

0.0292331

Years of Education

-0.004811

0.00882

0.5888

-0.022699

0.0130769

Median Age
0.000993 0.003878 0.7994 -0.006872 0.0088584
(IgG %+ Samples)*E4
[N]
-0.00064 0.000665 0.3421 -0.001989 0.0007084
Outcome variables of the generalized linear model of IgG on the Attention cognitive domain.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.
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Table 4b: Generalized Linear Model of Anti-HHV6 IgG on Executive Function
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept
Baseline MMSE zscore

-0.135131

0.961195

0.8891

-2.090698

1.8204357

0.0023364 0.022862

0.9192

-0.044176

0.048849

IgG %+ Samples

0.001258

0.001697

0.4638

-0.002195

0.0047111

E4 [N]

-0.106159

0.063793

0.1056

-0.235948

0.0236294

Sex [Female]

-0.023089

0.064781

0.7238

-0.154888

0.1087094

Years of Education

-0.006139

0.026052

0.8152

-0.059143

0.0468647

Median Age
0.0037594 0.010208
0.715
-0.017009 0.0245279
(IgG %+ Samples)*E4
[N]
-0.001302 0.00167
0.4412
-0.0047
0.0020958
Outcome variables of the generalized linear model of IgG on the Executive Function cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.

Table 4c: Generalized Linear Model of Anti-HHV6 IgG on Global Cognition
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.3914162 0.663415

0.5595

-0.961628

1.7444604

Baseline MMSE zscore

-0.002967

0.024273

0.9035

-0.052471

0.0465371

IgG %+ Samples

0.0017111 0.001326

0.2064

-0.000993

0.0044152

E4 [N]

0.0571656 0.045904

0.2223

-0.036456

0.1507875

Sex [Female]

-0.040066

0.047572

0.4061

-0.137089

0.0569569

Years of Education

0.0077961

0.01819

0.6712

-0.029302

0.0448944

Median Age

-0.009394

0.007159

0.1991

-0.023995

0.0052072

(IgG %+ Samples)*E4
[N]
1.30E-05 0.001336 0.9923
-0.002711 0.0027368
Outcome variables of the generalized linear model of IgG on Global Cognition. Variables with a
Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele is present, either
heterozygous or homozygous.
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Table 4d: Generalized Linear Model of Anti-HHV6 IgG on Language
Lower
Term
Estimate Std Error Prob>|t|
95%

Upper
95%

Intercept
Baseline MMSE zscore

-0.110792

0.405709

0.7866

-0.93824

0.7166567

-0.010518

0.019453

0.5926

-0.050192

0.029156

IgG %+ Samples

0.0016279

0.00072

0.0309*

0.0001596

0.0030961

E4 [N]

0.0515978 0.027585

0.0709

-0.004662

0.1078573

Sex [Female]

0.0106749 0.029977

0.7242

-0.050465

0.0718144

Years of Education

0.0086561 0.009579

0.3731

-0.01088

0.028192

Median Age
-0.002584 0.004346 0.5564 -0.011448 0.0062799
(IgG %+ Samples)*E4
[N]
-0.001119 0.000735 0.1381 -0.002619 0.0003803
Outcome variables of the generalized linear model of IgG on the Language cognitive domain.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.

Table 4e: Generalized Linear Model of Anti-HHV6 IgG on Processing Speed
Lower
Upper
Term
Estimate
Std Error Prob>|t| 95%
95%
Intercept
Baseline MMSE zscore

-0.011232

0.448147

0.9802

-0.922994

0.9005309

-0.03543

0.016302

0.0370*

-0.068598

-0.002263

IgG %+ Samples

0.0004736 0.000747

0.5306

-0.001047

0.0019941

E4 [N]

0.0036221 0.029354

0.9025

-0.056099

0.0633433

0.030288

0.7044

-0.073211

0.0500301

0.0102433 0.010189

0.322

-0.010485

0.0309721

Sex [Female]
Years of Education

-0.01159

Median Age
-0.001595 0.00477
0.7402
-0.0113
0.008110
(IgG %+ Samples)*E4
[N]
-0.00017 0.000783 0.8291
-0.001763 0.0014223
Outcome variables of the generalized linear model of IgG on the Processing Speed cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 4f: Generalized Linear Model of Anti-HHV6 IgG on Total Function
Lower
Term
Estimate Std Error Prob>|t|
95%
Intercept
Baseline MMSE zscore

0.1389085 0.173818

IgG %+ Samples

Upper
95%

0.4301

-0.215148

0.4929646

0.006555

0.999

-0.013343

0.0133603

0.0004414 0.000341

0.2054

-0.000254

0.001137

E4 [N]

-0.007998

0.011844

0.5043

-0.032123

0.0161272

Sex [Female]

-0.026461

0.012283

0.0389*

-0.051482

-0.001441

0.0008783 0.004685

0.8525

-0.008665

0.0104213

Years of Education

8.57E-06

Median Age
-0.002495 0.001864 0.1901 -0.006292 0.0013016
(IgG %+ Samples)*E4
[N]
-0.000165 0.000346 0.6361
-0.00087
0.0005394
Outcome variables of the generalized linear model of IgG on the Total Function cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.

Table 4g: Generalized Linear Model of Anti-HHV6 IgG on Verbal Fluency
Term

Estimate

Std Error

Prob>|t|

Lower 95%

Upper
95%

Intercept
Baseline MMSE zscore

0.2336025

0.377013

0.5396

-0.532581

0.9997861

0.0235651

0.014116

0.1042

-0.005123

0.0522528

IgG %+ Samples

-0.000258

0.000649

0.6938

-0.001576

0.0010606

E4 [N]

0.0411749

0.025193

0.1114

-0.010024

0.0923741

Sex [Female]

-0.001862

0.026992

0.9454

-0.056716

0.052992

Years of Education

-0.006674

0.008964

0.4616

-0.02489

0.0115423

Median Age

-0.002306

0.004041

0.572

-0.010519

0.0059065

(IgG %+ Samples)*E4
[N]
0.0000191 0.000677 0.9777
-0.001356 0.0013943
Outcome variables of the generalized linear model of IgG on the Verbal Fluency cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 4h: Generalized Linear Model of Anti-HHV6 IgG on Verbal Memory
Lower
Term
Estimate Std Error Prob>|t|
95%
Intercept
Baseline MMSE zscore
IgG %+ Samples
E4 [N]

Sex [Female]

Years of Education

0.845839

Upper
95%

0.441294

0.0635

-0.050036

1.7417142

0.0084968 0.014003

0.5479

-0.01993

0.0369237

-0.012774

0.6692

-0.072964

0.0474154

0.0008393 0.000833
-0.024316

0.029648
0.031142

0.0034494 0.010806

0.3204

-0.000851

0.4402

-0.087537

0.7515

-0.018487

0.0025298
0.038906

0.0253858

Median Age
-0.012106 0.004701 0.0144* -0.021649 -0.002563
(IgG %+ Samples)*E4
[N]
0.0004859 0.00086
0.5757
-0.00126
0.002232
Outcome variables of the generalized linear model of IgG on the Verbal Memory cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.

Table 5a: Generalized Linear Model of Anti-HHV6 IgM on Attention
Lower
Upper
95%
95%
Intercept
-0.200641 0.36231 0.5831 0.935439 0.5341564
E4 [N]
0.0340242 0.024187 0.1681 0.015028 0.0830767
Sex [Female]
-0.024389 0.02511 0.3379 0.075314 0.0265355
Educ
-0.006529 0.00851 0.4479 0.023787 0.0107288
Median Age
0.0018119 0.003902 0.6452 0.006102 0.0097255
Baseline MMSE z-score 0.0104584 0.011883 0.3846 0.013641 0.0345576
IgM %+ Samples
0.0009149 0.000575 0.1206 0.000252 0.0020818
(IgM %+ Samples)*E4 [N] -0.000292 0.000574 0.6137 0.001456 0.0008715
Outcome variables of the generalized linear model of IgM on the Attention cognitive domain.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.
Term

Estimate

Std Error
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Prob>|t|

Table 5b: Generalized Linear Model of Anti-HHV6 IgM on Executive Function
Term

Lower
95%

Upper
95%

Std Error

Prob>|t|

0.4227564 0.969854

0.6657

1.550427 2.3959394

E4 [N]

-0.128436

0.064367

0.0543

0.259391 0.0025189

Sex [Female]

-0.00984

0.065278

0.8811

0.142648 0.1229682

Educ

-0.011751

0.026431

0.6595

0.065525 0.0420232

Median Age

-0.00036

0.010505

0.9729

0.021732 0.0210117

0.0058558 0.023027

0.8008

0.040992 0.0527042

-0.000699

0.6528

0.003831 0.0024332

Intercept

Baseline MMSE z-score
IgM %+ Samples

Estimate

0.001539

(IgM %+ Samples)*E4
[N]
0.0008929 0.001484 0.5515 0.002126 0.0039119
Outcome variables of the generalized linear model of IgM on the Executive Function cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 5c: Generalized Linear Model of Anti-HHV6 IgM on Global Cognition
Prob>|t
Lower
Upper
Term
Estimate Std Error
|
95%
95%
0.261934 0.66379
Intercept
7
4
0.6958 1.091882 1.615752
0.059561 0.04680
0.155020
E4 [N]
8
5
0.2126 0.035897
9
0.04752
0.060218
Sex [Female]
-0.03671
5
0.4457 0.133638
8
0.008872 0.01835
0.046302
Educ
6
2
0.6322 0.028557
4
0.00727
0.007355
Median Age
-0.007488
8
0.3115 0.022332
6
0.02542
0.046264
Baseline MMSE z-score
-0.005583
2
0.8276 0.057431
7
0.00118
0.003739
IgM %+ Samples
0.001322
5
0.2733 0.001095
4
0.00111
0.001729
(IgM %+ Samples)*E4 [N]
-0.00055
8
0.626
0.002831
8
Outcome variables of the generalized linear model of IgM on Global Cognition. Variables with a
Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele is present, either
heterozygous or homozygous.
Table 5d: Generalized Linear Model of Anti-HHV6 IgM on Language
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept
-0.061853 0.417123 0.8831 -0.91258 0.7888742
E4 [N]
0.0508745 0.028525 0.0843 0.007304 0.1090526
Sex [Female]
0.0120709 0.030853 0.6983 0.050855 0.0749967
Educ
0.0059067 0.009676 0.546 0.013828 0.0256413
Median Age
-0.002172 0.004537 0.6355 0.011425 0.0070813
Baseline MMSE z-score -0.012832 0.019654 0.5186 0.052916 0.0272518
-7.961eIgM %+ Samples
0.0012914 0.000672 0.064
5
0.0026625
(IgM %+ Samples)*E4 [N] -0.000887 0.000659 0.1882 0.002232 0.0004576
Outcome variables of the generalized linear model of IgM on the Language cognitive domain.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.
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Table 5e: Generalized Linear Model of Anti-HHV6 IgM on Processing Speed
Term

Estimate

Std Error

Prob>|t|

Lower
95%

Upper
95%

0.442624

0.9058

0.953304 0.8477462

0.0037452 0.029338

0.8992

0.055943 0.0634339

Sex [Female]

-0.009753

0.030233

0.749

0.071263 0.0517576

Educ

0.012011

0.009924

0.2348

-0.00818

Median Age

-0.001204

0.004786

0.803

0.010941 0.0085333

0.016297

0.0533

0.065815 0.0004978

0.0001499 0.000674

0.8255

0.001222 0.0015222

Intercept
E4 [N]

Baseline MMSE z-score
IgM %+ Samples

-0.052779

-0.032659

0.0322016

(IgM %+ Samples)*E4
[N]
-0.0007
0.000676 0.3085 0.002076 0.0006766
Outcome variables of the generalized linear model of IgM on the Processing Speed cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 5f: Generalized Linear Model of Anti-HHV6 IgM on Total Function
Lower
Upper
Term
Estimate
Std Error Prob>|t| 95%
95%
Intercept
0.1449862 0.173056 0.4084 0.207517 0.4974897
E4 [N]
-0.007464 0.011951 0.5367 0.031808 0.0168794
Sex [Female]
-0.026714 0.01224 0.0365* 0.051645 -0.001783
Educ
-0.000025 0.004677 0.9958 0.009552 0.0095021
Median Age
-0.00226 0.001887 0.2398 0.006103 0.0015833
Baseline MMSE z-score -0.001063 0.006572 0.8725 -0.01445 0.0123235
IgM %+ Samples
0.0003954 0.000294 0.1877 0.000203 0.0009936
(IgM %+ Samples)*E4
[N]
1.11E-05 0.000283 0.9689 0.000564 0.0005867
Outcome variables of the generalized linear model of IgM on the Total Function cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.

Table 5g: Generalized Linear Model of Anti-HHV6 IgM on Verbal Fluency
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept
0.1469847 0.378466 0.7002 -0.62215 0.9161195
E4 [N]
0.045837 0.025283 0.0787 0.005545 0.0972186
Sex [Female]
-0.005781 0.026889 0.8311 0.060427 0.0488646
Educ
-0.006593 0.008747 0.4562 0.024369 0.0111833
Median Age
-0.001647 0.00412 0.6919 -0.01002 0.0067265
Baseline MMSE z-score 0.0208156 0.014124 0.1497 0.007888 0.0495195
IgM %+ Samples
0.0003336 0.000583 0.5709 0.000851 0.0015184
(IgM %+ Samples)*E4
[N]
0.0001863 0.000584 0.7517 0.001001 0.0013734
Outcome variables of the generalized linear model of IgM on the Verbal Fluency cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 5h: Generalized Linear Model of Anti-HHV6 IgM on Verbal Memory
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept
0.72457
0.429844 0.1008 -0.14806 1.5971996
E4 [N]
-0.007742 0.029169 0.7923 0.066958 0.0514753
Sex [Female]
-0.026661 0.029976 0.3799 0.087515 0.0341934
Educ
0.0022715 0.010135 0.824 0.018303 0.0228464
Median Age
-0.010315 0.004656 0.0333* 0.019767 -0.000863
Baseline MMSE z-score 0.0016214 0.014211 0.9098 0.027228 0.0304711
IgM %+ Samples
0.0011119 0.000708 0.1251 0.000325 0.0025486
(IgM %+ Samples)*E4
[N]
0.0006479
0.0007
0.3612 0.000774 0.0020697
Outcome variables of the generalized linear model of IgM on the Verbal Memory cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.

Table 6: Summary Statistics for ddPCR
Mean (Standard Deviation)
Cases
Age
84.8 (6.8)
Years of Education
16.2 (3.3)
% of cases (n)
E4 Allele Present
26.67 (12)
HHV6 Present
42.22 (19)
Latent HHV6 Present
40.00 (18)
Sex = F
64.44 (29)
Summary statistics for ddPCR measures. Age and education are presented as population mean
and standard deviation. The rest of the variables are presented as a percentage of the total
cases and the total number of cases that have that criterion.

49

Table 7a: Generalized Linear Model of ddPCR Variables on Attention
Term

Upper
95%

Estimate

Std Error

Prob>|t|

Lower 95%

Intercept

0.0195719

0.627501

0.9753

-1.260225

1.2993685

Years of education
Baseline MMSE zscores
Consensus
Diagnosis [AD]
Consensus
Diagnosis [CVD]

-0.011233

0.011956

0.3547

-0.035618

0.0131521

0.006323

0.010729

0.5599

-0.015559

0.0282045

0.0959762

0.084206

0.2631

-0.075762

0.2677146

-0.084775

0.073705

0.2589

-0.235097

0.065547

Latent Virus[N]

0.0150129

0.052335

0.7761

-0.091725

0.1217504

HHV6[N]

0.0327755

0.048186

0.5014

-0.065501

0.1310515

Age

1.35E-05

0.006953

0.9985

-0.014167

0.0141943

E4[N]

0.0187809

0.041526

0.6542

-0.065912

0.1034739

Sex [FEMALE]

0.0386841

0.042419

0.3688

-0.047831

0.1251993

Latent Virus[N]*E4[N] 0.0290232 0.044661 0.5206
-0.062063 0.1201096
Outcome variables of the generalized linear model of ddPCR variables on the Attention cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 7b: Generalized Linear Model of ddPCR Variables on Executive Function
Term
Estimate
Std Error Prob>|t| Lower 95% Upper 95%
0.121204
Intercept
4
1.11653
0.9145
-2.1832
2.4256091
0.003286
Years of education
2
0.029458 0.9121
-0.057511
0.0640837
Baseline MMSE zscores
9.25E-05 0.018144
0.996
-0.037354
0.0375395
Consensus Diagnosis
[AD]
-0.043833 0.137303 0.7523
-0.327214
0.2395471
Consensus Diagnosis
[CVD]
-0.040088 0.127838 0.7565
-0.303932
0.2237562
0.093991
Latent Virus[N]
4
0.096123 0.3379
-0.104398
0.2923804
HHV6[N]
-0.090197 0.086778
0.309
-0.269297
0.0889035
Age
-0.001012 0.011108 0.9282
-0.023938
0.0219146
E4[N]
-0.064593 0.074136 0.3922
-0.217602
0.0884151
0.097411
Sex [FEMALE]
4
0.091769
0.299
-0.091991
0.2868137
0.057734
Latent Virus[N]*E4[N]
2
0.080509 0.4802
-0.108427
0.2238958
Outcome variables of the generalized linear model of ddPCR variables on the Executive Function
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 7c: Generalized Linear Model of ddPCR Variables on Global Cognition
Upper
Term
Estimate
Std Error Prob>|t| Lower 95%
95%
Intercept

Years of education
Baseline MMSE zscores
Consensus
Diagnosis [AD]
Consensus
Diagnosis [CVD]

0.6046722

0.872571

0.4942

-1.185696

2.3950407

-0.015169

0.019589

0.4454

-0.055363

0.0250241

-0.043803

0.116773

0.7105

-0.283403

0.1957962

-0.088463

0.099511

0.3819

-0.292641

0.1157161

-0.009206

0.008917

0.311

-0.027502

0.0090894

0.0016043

Latent Virus[N]
HHV6[N]

0.0462535
0.0060209

E4[N]
Sex [FEMALE]

0.0593586
0.0228798

Age

0.022726

0.078299
0.069028
0.059322
0.065998

0.9442

0.5596
0.9311
0.3259
0.7315

-0.045026

-0.114402
-0.135613
-0.062359
-0.112536

0.0482341

0.2069087
0.1476551
0.1810764
0.1582958

Latent Virus[N]*E4[N] -0.083608 0.06428
0.2044
-0.2155
0.0482845
Outcome variables of the generalized linear model of ddPCR variables on Global Cognition.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.

Table 7d: Generalized Linear Model of ddPCR Variables on Language
Term
Estimate
Std Error Prob>|t| Lower 95% Upper 95%
Intercept
0.410252 0.520056 0.4366
-0.653382
1.4738865
Years of education
-0.005857 0.011542 0.6157
-0.029464
0.0177503
Baseline MMSE zscores
-0.001329 0.012035 0.9128
-0.025944
0.0232853
Consensus
Diagnosis [AD]
-0.035992 0.069984 0.6109
-0.179126
0.107142
Consensus
Diagnosis [CVD]
0.0207507 0.058207
0.724
-0.098295
0.1397967
Latent Virus[N]
0.0199196 0.041356 0.6337
-0.064663
0.1045021
HHV6[N]
-0.023754 0.038615 0.5433
-0.10273
0.0552221
Age
-0.004078 0.005314
0.449
-0.014946
0.0067895
E4[N]
0.0067294 0.033336 0.8414
-0.061451
0.0749094
Sex [FEMALE]
-0.001386 0.038158 0.9713
-0.079428
0.0766567
Latent Virus[N]*E4[N] 0.0561183 0.036258 0.1325
-0.018038
0.1302745
Outcome variables of the generalized linear model of ddPCR variables on the Language cognitive
domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE
E4 allele is present, either heterozygous or homozygous.
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Table 7e: Generalized Linear Model of ddPCR Variables on Processing Speed
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%

Intercept
0.5845841 0.535192 0.2844
-0.51354
1.6827081
Years of education
0.0299594 0.010092 0.0062* 0.0092522 0.0506666
Baseline MMSE zscores
0.0058447 0.008835 0.5139
-0.012284 0.0239732
Consensus
Diagnosis [AD]
0.0640351 0.070149 0.3694
-0.0799
0.2079697
Consensus
Diagnosis [CVD]
-0.024301 0.065443 0.7133
-0.158579 0.1099778
Latent Virus[N]
0.1131556 0.046045 0.0207*
0.01868
0.2076312
HHV6[N]
-0.006947 0.040902 0.8664
-0.090871 0.0769778
Age
-0.011813 0.006012 0.0598
-0.024148 0.0005216
E4[N]
-0.008498 0.035246 0.8113
-0.080816
0.063821
Sex [FEMALE]
-0.036439 0.036431 0.3261
-0.11119
0.038312
Latent Virus[N]*E4[N] -0.010809 0.039079 0.7842
-0.090993
0.069374
Outcome variables of the generalized linear model of ddPCR variables on the Processing Speed
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 7f: Generalized Linear Model of ddPCR Variables on Total Function
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.0239502 0.304107

0.9378

-0.60115

0.6490505

Years of education
Baseline MMSE zscores
Consensus
Diagnosis [AD]
Consensus
Diagnosis [CVD]

0.0062673 0.006378

0.3349

-0.006844

0.0193784

-0.001358

0.006342

0.8322

-0.014395

0.0116792

0.0030696 0.040133

0.9396

-0.079425

0.0855645

-0.007907

0.036768

0.8314

-0.083485

0.0676715

Latent Virus[N]

0.0310273 0.025529

0.2351

-0.021447

0.083502

HHV6[N]

0.005889

0.023158

0.8013

-0.041713

0.0534906

Age

-0.001676

0.003441

0.6303

-0.008749

0.0053965

E4[N]

-0.022407

0.020114

0.2755

-0.063752

0.018938

Sex [FEMALE]
0.0132999 0.023358 0.574
-0.034713 0.0613125
Latent
Virus[N]*E4[N]
0.0025823 0.021422 0.905
-0.04145
0.046615
Outcome variables of the generalized linear model of ddPCR variables on the Total Function
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 7g: Generalized Linear Model of ddPCR Variables on Verbal Fluency
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

-0.174178

0.657346

0.7928

-1.514843
-0.021514

0.0295763

0.0067865 0.011239

0.5504

-0.016136

0.0297087

0.0757844

0.08821

0.3969

-0.104122

0.2556908

-0.02149

Years of education
Baseline MMSE zscores
Consensus
Diagnosis [AD]
Consensus
Diagnosis [CVD]

0.0040312 0.012525

0.07721

0.7826

-0.178961

0.1359815

Latent Virus[N]

0.0604534 0.054824

0.2787

-0.051361

0.1722674

-9.422e-5

0.007284

0.9898

-0.014949
-0.096598

0.014761

0.0808442

0.0165121 0.044437

0.7127

-0.074118

0.107142

HHV6[N]
Age

E4[N]
Sex [FEMALE]

0.0013114 0.050478
-0.007877

0.043501

0.7497

1.166487

0.9794
0.8575

-0.101639

0.1042616

Latent Virus[N]*E4[N] 0.0642463 0.046785 0.1795
-0.031172 0.1596648
Outcome variables of the generalized linear model of ddPCR variables on the Verbal Fluency
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
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Table 7h: Generalized Linear Model of ddPCR Variables on Verbal Memory
Lower
Upper
Term
Estimate Std Error Prob>|t|
95%
95%
Intercept

0.1748102 0.498357

0.7282

-0.84297

1.1925905

0.0070006

0.00987

0.4836

-0.013157

0.0271585

0.0027178 0.008807

0.7598

-0.015268

0.0207036

0.0244211

0.07226

0.7377

-0.123154

0.1719964

-0.122169

0.06056

0.0527

-0.245849

0.0015115

0.0488775 0.042953

0.2642

-0.038844

0.136599

HHV6[N]

-0.027632

0.04076

0.503

-0.110876

0.0556115

Age

-0.004513

0.005505

0.4188

-0.015756

0.0067303

0.0082986 0.034306

0.8105

-0.061764

0.0783612

-0.016816

0.6174

-0.08486

0.0512282

Years of education
Baseline MMSE zscores
Consensus
Diagnosis [AD]
Consensus
Diagnosis [CVD]
Latent Virus[N]

E4[N]
Sex [FEMALE]

0.033318

Latent Virus[N]*E4[N] 0.0574442 0.038078 0.1419
-0.020321 0.1352093
Outcome variables of the generalized linear model of ddPCR variables on the Verbal Memory
cognitive domain. Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic.
E4 = ApoE E4 allele is present, either heterozygous or homozygous.
Table 8a: Generalized Linear Model of ddPCR Variables on Thal Staging
Lower
Term
Estimate
Std Error Prob>|t|
95%
Upper 95%
Intercept
11.758442 4.0447802 0.0061* 3.5629392
19.953945
Years of Education
Latent Virus [N]
HHV6 [N]
Age

E4 [N]

SEX [FEMALE]

0.1035174 0.0843239

0.2273

-0.067339

0.2743739

-0.534743

0.1557

-1.282391

0.2129050

-0.025217

0.4112692

-0.112569

0.0449099 0.0167*

-0.071955
-0.625568

0.3689917
0.326803

0.3110800

0.9514

0.8269
0.0517

-0.858528
-0.203565
-0.734121
-1.255876

0.8080929
-0.021572

0.5902116
0.0047398

Latent Virus [N]*E4 -0.138534 0.3387044 0.6849 -0.824814
0.5477460
[N]
Outcome variables of the generalized linear model of ddPCR variables on Thal staging. Variables
with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele is present,
either heterozygous or homozygous.

56

Table 8b: Generalized Linear Model of ddPCR Variables on CERAD Staging
Lower
Term
Estimate
Std Error Prob>|t|
95%
Upper 95%
Intercept
7.4525334 2.3920363 0.0035* 2.6058075
12.299259
Latent Virus [N]

0.1522323 0.2432199

0.5352

Age
Years of Education

-0.077780 0.0265592
0.0541884 0.049868

0.0058*
0.2842

-0.075175

0.6995

HHV6 [N]

Sex [FEMALE]
E4 [N]

-0.397292

0.2182174

-0.435786

0.1839691
0.1932678

-0.34057

0.6450427

-0.131594
-0.046854

-0.02396
0.1552310

0.0768

-0.839443

0.0232*

-0.80854

-0.466773

0.0448576

-0.063029

0.3164223

Latent Virus [N]*E4 -0.207820 0.2003058 0.3062
-0.61367
0.1980380
[N]
Outcome variables of the generalized linear model of ddPCR variables on CERAD staging.
Variables with a Prob>|t| are bolded. OTC = Over the counter anti-herpetic. E4 = ApoE E4 allele
is present, either heterozygous or homozygous.

57

Figure 1: HHV-6 drives significant differential expression of multiple functional domains in the
temporal region. The total number of genes differentially expressed in each region were
grouped based on NanoString’s functional gene directory. Total number of both up and down
regulated genes are plotted for each domain in A) the SMTG, B) the cerebellum, and C) both
regions.
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Please ü the ⃝ to say whether or not you have had each medical condition.
Chicken pox
Shingles
Anxiety
Depression

Medical Condition

Yes
⃝
⃝
⃝
⃝

No
⃝
⃝
⃝
⃝

Unsure
⃝
⃝
⃝
⃝

Please ü the one ⃝ for about how many cold sores or fever blisters you experienced in the past year.
⃝
None (zero)

⃝
A Few (1 to 3)

⃝
Several (4 to 7)

⃝
Too many to track (>7)

⃝
Not sure

Please ü the one ⃝ for the frequency of cold sores or fever blisters you experienced in the past 5 years.
⃝
None

⃝
Infrequent

⃝
Frequent

⃝
Not sure

Please ü the one ⃝ for the severity of cold sores or fever blisters you experienced in the past 5 years.
⃝
Negligible

⃝
Minor inconvenience

⃝
Major inconvenience

⃝
Not sure

For each over-the-counter medications, please ü the one ⃝ that best describes how many times you have
ever used it for treating cold sores or fever blisters. (Do not count times used to treat pain related to tooth
or gum decay or damage.)
Medication
Abreva
Lip Clear Lysine+
Releeve
Blistex
Orajel

Never
⃝
⃝
⃝
⃝
⃝

3 or fewer times
⃝
⃝
⃝
⃝
⃝

4 or more times
⃝
⃝
⃝
⃝
⃝

Please ü the ⃝ for whether or not you have had each of the following surgeries.
Surgery
Root canal
Wisdom tooth removal
Dental implants
Jaw surgery
Bone grafts involving face or jaw
Rhinoplasty (“nose job”)
Rhytidectomy (“face lift”)
Facial reconstructive surgery

Yes
⃝
⃝
⃝
⃝
⃝
⃝
⃝
⃝
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No
⃝
⃝
⃝
⃝
⃝
⃝
⃝
⃝

Unsure
⃝
⃝
⃝
⃝
⃝

Unsure
⃝
⃝
⃝
⃝
⃝
⃝
⃝
⃝

For each statement below, please ü the one ⃝ that best applies to how often you have felt that feeling
over the past month.
In the past month...
Never

Almost
Fairly Very
Never Sometimes Often Often

How often have you been upset because of something
that happened unexpectedly?

⃝

⃝

⃝

⃝

⃝

How often have you felt that you were unable to
control the important things in your life?

⃝

⃝

⃝

⃝

⃝

How often have you felt nervous and stressed?

⃝

⃝

⃝

⃝

⃝

How often have you felt confident about your ability to
handle your personal problems?

⃝

⃝

⃝

⃝

⃝

How often have you found that you could not cope
with all the things that you had to do?

⃝

⃝

⃝

⃝

⃝

How often have you been able to control irritations in
your life?

⃝

⃝

⃝

⃝

⃝

How often have you felt that you were on top of
things?

⃝

⃝

⃝

⃝

⃝

How often have you been angered because of things
that happened that were outside of your control?

⃝

⃝

⃝

⃝

⃝

How often have you felt difficulty were piling up so
high that you could not overcome them?

⃝

⃝

⃝

⃝

⃝

Supplemental Figure 1: Copy of Survey Sent to Study Participants. Also included were a page for
collecting basic information and a short summary of what the survey hoped to capture.
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Supplemental Table 1: List of Differentially Expressed Genes in Superior Medial Temporal Gyrus
Fold
Change
Effect
Effect
Compared
Compared
Compared
to
to
to
Probe Uninfecte
Probe
Uninfecte
Probe
Uninfecte
Name
d
P value
Name
d
P value
Name
d
P value
0.0061508
C4A
2.24 3.90E-05
FSCN1
1.22
3
LACC1
-1.44 0.008843
0.0019691
0.0081030
0.0001378
1
2
8
HSPB1
2.1
KAT2B
1.22
SUMO1
-1.44
0.0004603
0.0011560
MBD3
1.95
6
PARP1
1.22 2.66E-05
CCL5
-1.45
3
0.0049424
0.0007938
AXL
1.88 0.0002581
TBR1
1.22
5
CD36
-1.45
3
0.0034265
BAG3
1.78
2 ATP6V0E1
1.21 0.0081087
EGR1
-1.45 0.0118078
0.0006943
0.0079741
0.0020653
3
9
3
CSF1
1.76
HDAC4
1.21
HRK
-1.45
0.0003101
0.0001926
0.0022133
IGF1R
1.76
6 MAP2K4
1.21
6
TREM1
-1.45
9
0.0001483
0.0005556
0.0048647
2
2
9
ITGAV
1.74
MTO1
1.21
IL1B
-1.46
0.0012738
0.0012081
0.0007934
SPP1
1.71
8
TLE3
1.21
7 ANAPC15
-1.47
6
0.0006148
0.0041448
9
9
PLEKHB1
1.7 1.44E-05 TXNRD1
1.21
EGFR
-1.47
0.0008010
0.0036740
TGFB1
1.69
9
GRIA2
1.2 0.0055698
KCND1
-1.47
8
0.0029662
0.0084246
0.0095479
4
1
8
RAPGEF3
1.66
ABL1
1.19
KDM4D
-1.47
0.0024722
0.0091011
EEF2K
1.62
7
BIRC2
1.19 0.0038216
LILRB4
-1.47
8
0.0016791
0.0108503
0.0001315
7
5
4
FABP5
1.61
COX5B
1.19
HMGB1
-1.48
0.0053882
BCL2L1
1.59 1.66E-05
TFG
1.19 0.0041694 PLA2G4A
-1.48
3
0.0013600
0.0082896
2
3 TMEM64
SYP
1.58
BAX
1.17
-1.48 8.79E-05
0.0002673
PIK3R2
1.56
1
CCNI
1.17 0.0039694
BLNK
-1.49 0.0065645
0.0163047
0.0004795
6 MAPK14
9
PLXNB3
1.56
1.17
CDK20
-1.5 6.87E-06
0.0003957
0.0060737
TNFRSF1A
1.56
2
RPS3
1.17 0.0075608
TRAT1
-1.51
2
0.0009051
0.0011363
0.0112115
8
7
6
SESN2
1.55
TRAF3
1.16
HPGDS
-1.52
0.0027714
0.0021889
0.0029050
KAT2A
1.54
5
BCL2L2
1.15
3
IL21R
-1.53
6
0.0084201
0.0003070
0.0156842
2
5
1
S1PR5
1.54
BRAF
1.15
ATF3
-1.55
0.0026701
0.0048544
BCL2
1.53 0.0043803
AARS
1.13
6
CD24
-1.55
8
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CNP

0.0010711
6
0.0019035
1.52
2
0.0154910
5
1.5
0.0066206
1.49
7

GJA1

1.49

FANCG
CYP27A1
FA2H

1.53

MAFB

0.002434
0.0079791
1.49
6

APC

1.48

DDB2

9.26E-05
0.0031267
1.47
1

SQSTM1

1.47

EIF1

1.46

RELA

1.46

ERCC2

1.44

TUBB4A

1.42

AKT2

1.41

BOK

1.41

RPS9

1.4

SOX10

1.4

IRAK2

1.38

LAMP2

1.38

AGT

1.37

KMT2A

1.37

UGT8
CALCOCO
2

1.37

CLSTN1

1.36

ALDH1L1

1.35

GRN

1.35

1.36

5.23E-06

KDM4B

1.13

RAC1

1.13

KDM2B

1.12

TADA2B

1.11

ASPH

1.1

LARS

-1.12

TBP

-1.12

EPG5

-1.14

TOPBP1

7.38E-05
RBFOX3
0.0064823
1
NCOR1
0.0040207
7
PMS2
0.0012557
8 TSPAN18
0.0004546
8
ATG5
0.0040930
9
MRE11
0.0035162
7 SMARCD1
0.0135855
4 RPL36AL
0.0019115
6 SMARCA4
0.0005239
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Supplemental Table 1: Comprehensive table of all significantly differentially expressed genes in
the SMTG with their relative change compared to uninfected controls, as well as the p-value of
the comparison between the infected and uninfected groups.
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Supplemental Table 2: List of Differentially
Expressed Genes in Cerebellum
Fold Change
Probe
Compared to
Name
Uninfected
P value
FBLN5
-1.49
0.00175557
TBR1
-1.4
0.00169583
RB1CC1
-1.23
0.00178314
PMS2
-1.22
0.00128506
RAD17
-1.2
0.00145578
KDM5A
1.11
0.00185615
BAD
1.14
0.00090057
EP300
1.14
0.00036989
CSK
1.16
0.00073813
BRD4
1.17
0.00085979
PRDX1
1.17
0.00153911
AMBRA1
1.18
0.00026742
RHOA
1.18
0.00173848
BIN1
1.19
0.00046696
SQSTM1
1.19
0.00124721
DNMT1
1.21
2.92E-06
SUZ12
1.23
0.00068277
CREBBP
1.24
0.00049058
LDLRAD3
1.25
0.00025054
NRM
1.29
0.00146013
PTMS
1.33
0.00013074
SESN2
1.37
0.00046044
RELA
1.39
9.72E-06
IRAK2
1.46
0.00040012
TRAF2
1.46
0.00073217
FANCC
1.48
0.00105065
CASS4
1.57
0.00064767
CHEK1
1.62
0.00057825
Supplemental Table 2: Comprehensive table of all significantly differentially expressed genes in
the cerebellum with their relative change compared to uninfected controls, as well as the pvalue of the comparison between the infected and uninfected groups.
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Supplemental Table 3: List of
Differentially Expressed Genes
Conserved Between Both Regions
Fold
Change
Compared
Probe
to
Name
Uninfected P value
FBLN5
-1.49 0.00175557
TBR1
-1.40 0.00169583
RB1CC1
-1.23 0.00178314
PMS2
-1.22 0.00128506
KDM5A
1.11 0.00185615
EP300
1.14 0.00036989
BRD4
1.17 0.00085979
PRDX1
1.19 0.00153911
BIN1
1.19 0.00046696
SQSTM1
1.19 0.00124721
CREBBP
1.24 0.00049058
SESN2
1.37 0.00046044
RELA
1.39
9.72E-06
IRAK2
1.46 0.00040012
Supplemental Table 3: Comprehensive table of all significantly differentially expressed genes in
both regions with their relative change compared to uninfected controls, as well as the p-value
of the comparison between the infected and uninfected groups in the cerebellum.
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CHAPTER 3: Assessing the Effect of HHV-6 Infection on the Distribution and Functional Capacity
of Microglia and Associated T-cell Involvement
Introduction:
Human herpesvirus 6 (HHV-6) has been implicated in the causation and progression of
Alzheimer’s disease (AD)61, 63, 74. Studies have shown similar patterns of gene expression changes
between HHV-6 infected brains and AD affected brains, suggesting a potential link61. Of
particular interest in this context is how HHV-6 might be affecting microglia, the primary
immune cell of the brain. HHV-6’s wide tropism includes microglia, and studies have shown that
HHV-6 is able to establish latency within microglia55, 65, 74, 96, 120. Given the propensity of latent
herpesviruses to modulate gene expression of host cells, it stands to reason that the same might
potentially be true in the case of microglia55, 74, 96, 120.
Microglia are critical in the proper processing of amyloid beta (Ab) and microtubule
associated protein tau (MAPT), the two primary protein aggregates found in AD16, 24-27, 29, 121.
Evidence suggests microglial mediated inflammation and phagocytosis is beneficial in the
clearance of these aggregates in the short term, but detrimental in the long term due to off
target inflammatory effects16, 24-27, 29, 121. The exact timing and determinants of when this flip
from beneficial to detrimental occurs is not well understood, but research suggests it is a finely
tuned system16, 24-27, 29, 121. As such, alterations due to the presence of latent HHV-6 may provide
enough of an impetus to tip the inflammatory balance, or outright prevent critical functions
needed for the clearance of these protein aggregates. While our previous results indicate that
HHV-6 appears to have no impact on the ultimate severity of neuropathology, it still might be
affecting the neuroinflammation generated in association with the pathology.
Previous work from our lab has shown evidence of differential regulation of genes
related to microglial activation and activity as a function of HHV-6 in Alzheimer’s disease
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autopsy tissue (Chapter 2). In addition, we also observed changes in genes related to the
recruitment of circulating lymphocytes, such as T-cells (Chapter 2). This finding gave rise to a
secondary question: given HHV-6’s reservoir within T-cells, is this recruitment an additional
method of entry into the central nervous system (CNS) beyond the olfactory or facial cranial
routes55, 65, 96? Essentially, we wanted to identify whether T-cells being recruited to the CNS are
adding to the unresolved inflammatory microenvironment by introducing additional virus.

As such, we set out to 1) identify changes in microglial distribution, activation, and
morphology in autopsy cases of AD in the context of HHV-6 infection; 2) elucidate alterations in
phagocytic capacity of microglia when infected with HHV-6, and how ApoE genotype influences
any effects of the infection; and 3) identify the location of HHV-6 and T-cells relative to Ab
plaques. We hypothesized that the presence of HHV-6 will result in a more dystrophic microglial
profile, while also seeing decreases in activation and distribution in the temporal lobe. Secondly,
we hypothesized that HHV-6 infection will decrease phagocytic capacity of primary microglia,
and the e4 isoform of ApoE will exacerbate this decrease. Finally, we hypothesized that both Tcells and HHV-6 will frequently be found within the same plaques, indicating recruitment of
infected T-cells and subsequent contribution to existing pathology.

Methods and Reagents:

Animals:
Human ApoE 3/3 and 4/4 homozygote knock-in mice provided by Dr. Lance Johnson were used
for this study122, 123. The study was approved by the University of Kentucky Institutional Animal
Care and Use Committee and conformed to the National Institutes of Health Guide for the Care
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and Use of Animals in Research. All studies were performed blinded. All studies were completed
in compliance with the Animal Research: Reporting In Vivo Experiments guidelines124, 125.

Primary Microglial Culture:
P0-P3 pups were euthanized, meninges removed, and cortices were dissected out. Physical
dissociation of the cortices with scissors was followed by a 20-minute 0.25% trypsin-EDTA (INFO)
incubation at 37°C with gentle inversions of the samples every 5 minutes. Equal volume of
growth media (50:50 DMEM:Ham’s F-12 w/ 10% fetal bovine serum and 1% penicillinstreptomycin) was added to each sample to neutralize trypsin, and then centrifuged at 300rcf
for 5 minutes. Media and trypsin were then aspirated carefully. Pellet was washed 3x with HBSS
before resuspending in 10mL of growth media. Samples were then triturated until no large
chunks were visible and a fine suspension had been achieved. The suspension was then filtered
through a 70µm cell filter, followed by an additional 10mL of growth media to ensure no cells
adhered to the filter. Cells were then plated into cell culture treated T75 flasks at a ratio of 1
flask per whole brain cortex. Flasks were placed in a 37°C incubator with 5% carbon dioxide.
Media was replaced the following day to remove non-adherent or dead cells, and then again, a
week after. At 2 weeks past plating, plates were shaken for an hour and 45 minutes in an
incubator at 37°C with 5% carbon dioxide. This shakes the microglia loose as they are the least
adhered cells present in the culture. Media was then collected and then centrifuged at 300rcf
for 10 minutes. The supernatant was aspirated gently, and the pellet resuspended in 0.5mL of
growth media before counting via trypan blue staining. Cells were plated onto coverslips placed
into the wells of 12 well plates with about 30,000 cells per well. Plates were placed back into the
incubator overnight to allow microglia time to attach to the coverslips before performing
experiments.
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Phagocytosis Assays:
Phagocytosis assays were performed as previously reported126. Briefly, SupT cells (From Dr.
Dharam Ablashi) either with (HHV-6 Foundation: HHV-6 B Z29 Strain in SupT-1 cell)) HHV-6 or
without were added in a 1:1 ratio to the microglia wells for 15 minutes. Media was then
aspirated from the wells and serum free DMEM/F-12 media was added to each well for 1 hour
to promote homeostatic microglial conditions and latent establishment of the virus. During this
hour, fluorescent latex beads (Sigma: L1030-1ML) were pre-opsonized in FBS at 37°C (1:5 beads
to FBS). The FBS/bead mixture was added to serum free DMEM/F12 in order to achieve a final
0.01% concentration of beads in solution. Media on microglia was then replaced with beadcontaining media for 1 hour and placed into the incubator at 37°C and 5% carbon dioxide. Wells
were washed with 5x with ice-cold PBS and then fixed with 10% formalin for 15 minutes. Fixed
cells were then washed 3x with PBS, then incubated for 30 minutes in a blocking solution (0.2%
triton-X, 4% goat serum, 0.019% L-lysine in PBS). Cells were then incubated in primary antibody
solution (fluorescently tagged IBA-1 – 1:1000, HHV-6 (gp60+gp100) – 1:300) overnight. Cultures
were washed 3x with PBS before adding secondary antibody for HHV-6 antibody (2° - 1:1000)
for 1 hour. Cells washed 3x with PBS before mounting coverslips with DAPI containing mounting
media.

Autopsy Sample Collection:
All post-mortem tissue was provided by the Sanders-Brown Center on Aging Neuropathology
Core. Regions used were the hippocampus (HPC) and cerebellum (CERE). HPC is typically
affected in even mild AD cases, while the CERE only shows AD pathology in the most severe
cases. HHV-6 has been shown to infect both regions. We chose to include CERE as a de facto
pathology control region. 5µm thick serial sections were taken from paraffin-embedded tissue
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blocks. Adjacent sections were used as opposed to triple fluorescent labels (Granzyme B, HHV6, & Ab) due to anticipated issues with autofluorescence and low signal-to-noise ratio.

IBA-1 Staining:
Slides were deparaffinized in xylene, followed by sequential dips in 100% ethanol, 95% ethanol,
and 70% ethanol. Slides were then submerged in 1:15 dilution of DeClere antigen retrieval
buffer. EXR Retriever Version 3.0 was used for antigen retrieval. Slides were heated to 95°C for
12 minutes in the DeClere buffer, then washed in running distilled water for 5 minutes. Slides
were then incubated in 70% formic acid for 3 minutes, followed by a 10-minute wash in running
distilled water. Slides were then incubated in 10% methanol, 3% hydrogen peroxide in PBS for
15 minutes and washed 3x with PBS for 5 minutes each. Slides were then blocked in 0.2% tritonX, 4% goat serum, 0.019% L-lysine in PBS for 1 hour before incubating in primary antibody
solution (IBA-1 – 1:3000 in PBS w/ 4% goat serum) overnight. Slides were washed with PBS and
then incubated in secondary antibody solution (1:3000 in PBS w/ 4% goat serum) for 2 hours.
Sections were then treated for one hour with an ABC solution (Vectastain Elite ABC Kit, Vector
Laboratories, Burlingame, CA). Following another set of PBS washes, the sections were then
transferred into a DAB solution. Slides were washed another three times, dehydrated, and then
cover slipped. Slides were scanned on the Nikon Biopipeline at 10x magnification before
transferring to Indica Lab’s HALO Image Analysis software for further analysis.

IBA-1 Analyses:
Distribution: Binary percent area of positive staining was quantified in both regions assessed.
Statistical outliers were removed using the Grubbs’ Outlier test. ANOVA and each-way student’s
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t-tests were then performed between each group using JMP Statistical Software (JMP Pro 13).
Group averages and standard error of the mean were then plotted using GraphPad Prism 9.
Activation: The microglial activation analysis suite from HALO Image Analysis uses morphology
to assess activation status of microglia and is based on number of processes and their length.
Percentage of microglia activated was assessed in both regions of each case. Statistical outliers
were removed using the Grubbs’ Outlier test. ANOVA and each-way student’s t-tests were then
performed between each group using JMP Statistical Software (JMP Pro 13). Group averages
and standard error of the mean were then plotted using GraphPad Prism 9.
Morphology: Microglial morphology was assessed subjectively, according to previous studies,
via examination of 10 randomly selected 500µm squares a minimum of 100µm apart127. Briefly,
the following types of microglia were tallied in each square: ramified, hypertrophic, dystrophic,
rod-shaped, and amoeboid. The tallied values for each square were then averaged for each
region and case, and then each value converted to a proportion of all counted cells. Statistical
outliers were removed using the Grubbs’ Outlier test. ANOVA and each-way student’s t-tests
were then performed between each group using JMP Statistical Software (JMP Pro 13). Group
averages and standard error of the mean were then plotted using GraphPad Prism 9.

T-cell and amyloid staining:
Slides were deparaffinized and went through antigen retrieval and blocking as described above
for the IBA1 staining. Slides were incubated in primary antibody solution (Granzyme B – 1:1000
in blocking solution) overnight. Slides were washed with PBS and then incubated in secondary
antibody solution (1:3000 in blocking solution) for 2 hours. Slides were then rinsed with PBS
before incubating for 30 minutes in 500mL 70% ethanol supersaturated with 30g NaCl, made
alkaline with 2mL of 1% NaOH. A solution of 500mL 70% ethanol supersaturated with 30g NaCl
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and 1g of Congo Red was filtered via Buchner funnel until the solution was transparent. The
filtered Congo red solution was made alkaline with 2mL of 1% NaOH and slides were incubated
for 1 hour. Slides were then rinsed with PBS twice before incubating in 1:40 True-Black:PBS
solution for 10 minutes. Slides were rinsed with PBS twice, dehydrated, and cover-slipped with
DPX. Slides were imaged via the Nikon Biopipeline at 10x magnification before transferring to
Nikon Elements software for analysis. Number of plaques were counted in each HPC (none
present in CERE) and then those with Granzyme B colocalized were tallied. Each case then had a
proportion of plaques with Granzyme B to total plaques. Statistical outliers were removed using
the Grubbs’ Outlier test. ANOVA and each-way student’s t-tests were then performed between
each group using JMP Statistical Software (JMP Pro 13). Group averages and standard error of
the mean were then plotted using GraphPad Prism 9.

HHV-6 and amyloid staining:
Slides were deparaffinized and went through antigen retrieval as described above for the IBA1
staining. Slides were then incubated in 70% formic acid for 3 minutes, followed by a 10-minute
wash in running distilled water. Slides were blocked, before incubating in primary antibody
solution (HHV-6 gp60+gp100 – 1:500 in blocking solution) overnight. Slides were washed with
PBS and then incubated in secondary antibody solution (1:3000 in blocking solution) for 2 hours.
Slides were then rinsed with PBS before counter-staining with Congo red as described above.
Slides were imaged via the Nikon Biopipeline at 10x magnification before transferring to Nikon
Elements software for analysis. Number of plaques were counted in each HPC (none present in
CERE) and then those with HHV-6 colocalized were tallied. Each case then had a proportion of
plaques with HHV-6 to total plaques. Statistical outliers were removed using the Grubbs’ Outlier
test. ANOVA and each-way student’s t-tests were then performed between each group using
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JMP Statistical Software (JMP Pro 13). Group averages and standard error of the mean were
then plotted using GraphPad Prism 9.

Statistics:
Statistics for each experiment were carried out as described above. Normality of each data set
was assessed via visual inspection and application of the Shapiro-Wilks test for normality using
JMP. Non-parametric data sets were analyzed using Wilcoxon tests, as opposed to t-tests for
parametric data sets. Appropriate adjustments to figures containing non-parametric data are
reported in each figure legend.

Results:

Microglia:
Distribution: No differences were observed in terms of binary % area IBA-1 staining in the CERE
based on HHV-6 (Fig. 1B), however, we did observe a significant increase in the % area of IBA-1
in HHV-6 positive cases (Fig. 1A).
Activation: No differences were observed in either region in terms of the activated proportion of
microglia based on HHV-6 present (Fig. 1C&D). We also did not observe any difference in terms
of the average process length per microglia in either region between those with or without HHV6 (Fig. 1E&F).

Morphology: No differences were observed in terms of morphology between regions or within
regions between those with or without HHV-6 (Fig. 2).
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Phagocytosis: We observed a significant increase in the percentage of phagocytic cells in
uninfected E4 microglia compared to both uninfected and infected E3 and wild type microglia
(Fig. 3A). This could be, in part, due to a relatively high level of variance within this group. The E4
infected microglia were, on average, more phagocytic than either E3 or wild type under either
condition, though the E4 infected group is not significantly different from any of the other
groups.

T-Cells and HHV-6 w/ Ab: Total plaques were counted for each case along with Granzyme B and
HHV6 positive plaques in both AD and Normal diagnosed cases. Granzyme B is a serine protease
found in the granules of cytotoxic T-cells and was used as a marker for cytotoxic T-cells in this
case. Some plaques were observed in normal cases, though none with Granzyme B positive
signal and very few with HHV6 positive signal (Figure 4A-C). We did observe more of both
Granzyme B and HHV6 positive plaques in AD cases, as expected. Qualitatively, distributions of
Granzyme B throughout the plaques were not predominantly within or around plaques and
seemed to vary in terms of position relative to the core of the plaques. The low amount of HHV6
in even AD cases suggests that it is not a common seed for plaques within this population.

Discussion:
Overall, we observed a minimal impact on microglial activation and function as a result
of HHV-6 infection. The only notable difference observed was in terms of the % of positive IBA-1
staining in the HPC (Fig. 1A). The higher area of microglia found in the HHV-6 positive cases
could have been indicative of more or longer processes (i.e., more ramified microglia compared
to activated, amoeboid microglia) but our activation analysis of the same tissue indicated this
was not the case (Fig. 1C). This would seem to indicate a higher number of microglia overall in
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the infected cases. This is an interesting finding, especially since the hippocampus is considered
one of the more microglia dense regions of the brain, along with the olfactory regions, which
serve as a potential entry point for various herpesviruses68, 73, 75, 96, 128. Perhaps there is a
connection between microglial density and susceptibility to HHV-6 infection due to the tropism
of the virus.
As mentioned above, no differences were observed in terms of overall activation of
microglia or average process length in either region (Fig. 1C-F). While this does seem to suggest
that HHV-6 does not play a significant role in terms of microglial reactivity, it is important to
note that we were assessing regional changes here. It would be interesting to see what changes
could be observed using single cell level assays on confirmed HHV-6 positive cells. This is a
potential area of future study.
The overall lack of differences in morphology again indicate HHV-6 was exerting minimal
to no influence on the microglial populations examined. We had anticipated an increase in the
dystrophic fraction in viral cases but saw no indication of this. This might be the result of the fact
that these were aged autopsy cases with high rates of dystrophic neurons present regardless of
virus129. It could also be potentially important to see if differences were present in younger
cases with or without HHV-6 that might indicate an earlier change in the ratio of dystrophic
microglia.
The increased phagocytosis in uninfected e4 microglia compared to e3 or WT under
either uninfected or infected conditions was surprising as we expected almost the opposite.
Previous literature suggested that ApoE e4 individuals experienced more aggressive spread and
more frequent reactivation of herpesviruses86, 87, 89. As such, we anticipated the infected e4
group to be most impacted by the HHV6 and potentially have the lowest level of phagocytosis
due to gene modulation by the virus. However, previous studies have shown that ApoE e4
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microglia have a higher basal inflammatory profile but react less effectively to insult or stimuli
that would normally merit an acute innate inflammatory response106. This may explain why the
uninfected e4 microglia were more phagocytic: they may have required less time/effort to
respond to the beads than their e3 or WT counterparts due to their heightened baseline of
inflammation. The HHV6 infection of the e4’s would then potentially cause a lowering of this
basal state, a trend which we observe, though not statistically significant.
What is more puzzling is the lack of response by the e3 or WT microglia in response to
virus. At the very least, we would expect the introduction of pathogens to the microglia to cause
an increase in inflammation leading to potentially higher levels of phagocytosis20, 33, 76. But we
observe no differences between infected and uninfected in either group. The monoculture
model of microglia used here may be a poor facsimile of the physiology that HHV6 interacts with
typically within the human body, and we may be missing key components that mediate HHV-6’s
impact on microglia. The monoculture also lacks any kind of immune system beyond the
microglia’s innate immunity, allowing the virus to infect and spread more rapidly. This means
that we might be unable to expose the microglia long enough to the virus without problematic
levels of cell death. If HHV-6’s effect on function occurs over a longer term, we may not have a
long enough time in this system to observe it. It is also possible that astrocytes or T-cells, which
HHV6 also infects, may play a role in the overall modulation of microglial function via secondary
signaling pathways, but as it stands now, it appears that we do not see HHV6 having a significant
effect on phagocytic capacity of microglia.
Our quantification of plaques with and without Granzyme B and HHV6 showed that
even in cases with pathology yet diagnosed as normal at autopsy, we did not see evidence of
either Granzyme B or HHV6 in any significant amount. AD cases on the other hand had a higher
amount of HHV6 and, especially, Granzyme B. It would appear, with our admittedly small
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sample size, that the association of T-cells with plaques seems to occur exclusively in more
severe AD cases and not in pre-clinical AD with limited amounts of pathology. Further, HHV6 is
also only observed in these more severe cases. One explanation is that in the more severe cases
the pathological burden is so great that T-cells that might be carrying HHV-6 or other pathogens
are recruited at a greater rate to help microglia resolve and clear plaques.
The overall low amount of HHV-6 associated with plaques also indicates that it is likely
not a common seed for the amyloid plaques in these cases. It is possible other pathogens are
acting as seeds. This is not an unforeseen outcome, as the evidence for HHV-6 seeding amyloid
plaques was weaker than a number of other pathogens, including HSV-162, 64, 96, 98, 130, 131. It does
not, however, rule out a role for HHV-6 in the development of AD pathology. Modulation of
innate inflammation is a key role that HHV-6 could still be influencing, though our microglial
data suggest that this does not seem to be occurring in the microglia.
Overall, this study shows HHV6 appears to have little impact on the distribution,
morphology, and phagocytic function of microglia. Further studies should potentially focus on
different cell types prone to HHV-6 infection that are involved in mediating the inflammation
associated with AD pathology, such as astrocytes or T-cells. We show evidence of an association
with T-cells and amyloid plaques in severe AD cases both with and without the presence of HHV6. The weak association between amyloid plaques and HHV-6 shown here also supports the idea
that HHV-6, if it is playing a role in AD progression, is not seeding amyloid plaques, or driving
aggregation directly. Further studies will focus on the interplay between T-cell recruitment and
activity within the brain under HHV-6 infected conditions.
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Table 1: Summary Statistics of Included Cases
Parameter
Mean (Standard Deviation)
Age (Years)
83.6 (6.4)
Years of Education
16.4 (2.1)
Parameter
% Of total (n)
Sex = Female
50 (11)
E4 Present = Yes
45.5 (10)
Consensus Diagnosis = AD
59.1 (13)
HHV-6 = Positive
36.4 (8)
Summary statistics for the included cases. Age and education are presented as population mean
and standard deviation. Rest of the variables are presented as the percentage of total and the
total number of cases that had the criterion in the left-most column.
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Figure 1: HHV-6 positive hippocampi showed a significant increase in IBA-1 area, but not in
terms of activation or process length. Percentage of IBA-1 staining within the (A) hippocampal
and (B) cerebellar regions for infected and uninfected cases are shown. The ratio of activated
microglia to total microglia for the (C) hippocampal and (D) cerebellar regions for each group is
shown as well. The average process length of microglia is also shown for the (E) hippocampal
and (F) cerebellar regions. All data are presented as the mean and standard error of the mean,
overlaid with individual data points, with each comparison by Student’s T-test. Comparisons
denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005, respectively.
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Figure 2: No difference in morphology due to presence of HHV-6 in either region. Percentages of
(A) ramified, (B) rod, (C) amoeboid, (D) hypertrophic, and (E) dystrophic microglia are presented
as group mean and standard error of the mean with individual points for each case examined
overlaid. Groups were compared by each-way Wilcoxon analysis. No significance were observed
to illustrate.
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Figure 3: E4 uninfected microglia display increased phagocytic activity relative to both E3 and
wild type under either infected or uninfected conditions. (Top) Percentage of counted cells with
a phagocytosed latex bead are displayed as mean and standard error of the mean for each
group, with individual data points for each replicate overlaid. All comparisons by studentized Ttest due to normal distribution. Comparisons denoted with *, **, and *** have p-values < 0.05,
0.01, and 0.005, respectively. (Bottom) Example image from infected E4 sample taken at 20x
magnification. These images illustrate both a positively phagocytosing cell and multiple without
beads present.
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Figure 4: Granzyme B and HHV-6 positive amyloid plaques identified in AD hippocampi tissue.
(A) Total, (B) Granzyme B positive, and (C) HHV6 positive plaque counts for AD and Normal
consensus diagnosed cases displayed as group mean and standard error of the mean with
individual counts overlaid. (D&E) Examples of fluorescently labelled and identified plaques with
positive granzyme B and HHV6 signal. Images taken at 20x magnification.
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CHAPTER 4: General Discussion
Data Chapter #1:
This study showed some minor relationships between markers of HHV-6 reactivation
and rate of cognitive decline. In the self-reported measures, we observed a slower decline in
verbal memory in individuals who had not had shingles. This aligns with previously observed
findings that showed that individuals with the shingles vaccine were less at risk of developing
AD112. Verbal memory is one of the cognitive domains most associated with AD132. While we did
not have access to patient vaccination records, we did see a significant decrease in the number
of people with shingles compared to those with chicken pox. We attribute this difference, at
least in part, to likely shingles vaccination in the population.
Shingles is specifically a reactivation of varicella zoster, another member of the
herpesvirus family65, 114. Importantly, it is found entirely in the periphery and not in the CNS127.
The reactivation occurs along major sensory nerves, which accounts for the considerable pain
associated with shingles127. The shingles vaccine has not been found to influence the activity of
other viruses, so it should not influence HHV-6 reactivation113, 114. Since we observed no other
reactivation associated with cognitive decline, this does seem to be a zoster specific interaction.
This suggests that peripheral reactivation of varicella zoster may have an impact on the
development of cognitive decline. This could be due to an increased flux in general inflammation
leading to cumulative perivascular damage in the blood brain barrier. The reactivation of zoster
causes significant peripheral inflammation and immune response that could potentially cause
damage throughout the periphery and along the vasculature of the brain65, 113, 114. This
inflammation and subsequent damage then has the potential to cause disruption of the blood
brain barrier via astrocyte feet uncoupling leading to hyperactivity of coupled neurons107, 125, 133.
This could be a coincidental event with AD, or potentially exacerbate AD pathology and
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inflammation. Part of this relies on the timing. If AD pathology is already present at the time of
the reactivation, then this additional vascular damage could add to the existing inflammation. If
pathology is present, but cognitive decline has not begun due to AD pathology, then vascular
damage and BBB disruption could generate cognitive symptoms coincidental with AD pathology.
Studies have shown extended peripheral inflammation contributes to cognitive declines in
animal models as well as humans134. It is therefore likely that the same could occur in this
cohort, though there is no explanation for zoster’s potent impact in a relatively short
reactivation timeframe.
The lack of relationships between anti-HHV-6 IgM and IgG and rates of cognitive decline
was not entirely unforeseen, as HHV-6 is incredibly ubiquitous, meaning IgG was not expected
to have much of an impact at all. IgM’s lack of influence is somewhat surprising based on
previous studies, but those studies were primarily related to HSV-170, 72, 93, 102. Anti-HSV-1 IgM
was associated with an elevated risk of AD diagnosis in a population based study70. Additionally,
anti-CMV IgM was found to have no effect on AD risk by itself, but had a synergistic effect with
anti-HSV-1 IgM72. Inherent differences between the viruses importantly includes tropism. HSV-1
is neurotropic, meaning it infects and reactivates from the neurons directly, rather than
microglia and astrocytes, as is the case with HHV-655, 65. This neurotropism is likely a key reason
it continues to be a focus within the infectious hypothesis. It means it can be found in neuritic
plaques that are a hallmark of AD53, 54. Additionally, direct involvement of neuronal function and
health means potential influence on cognitive function is substantial74, 91, 135.
Previous studies have shown that the presence of other herpesviruses, such as CMV or
HHV6, did not increase the risk of AD in patients, but a synergistic effect was observed when
HSV-1 was also present55, 72, 103. This relationship could be indicative of a larger susceptibility to
herpesviruses that also predisposes one to AD. It also could indicate some kind of interaction
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between the life cycles of the respective viruses that allows for more extensive reactivation and
spread. The most likely such interaction would likely be an overtasking of the immune system. In
essence, the reactivation of multiple viruses at once prevents an effective immune response to
one of them. It would be interesting to examine the temporal relationship between HSV-1 and
HHV-6 reactivations in this context. Are the reactivations simultaneous, suggesting this
overtasking? Are they consistently ordered if they are asynchronous, suggesting a priming by
one virus that leads to the reactivation of the other? An investigation of the impact of the timing
of multiple viral reactivations could be valuable.
Our screening of autopsy cases from the Sanders Brown Center on Aging longitudinal
cohort using ddPCR revealed that, while many cases had HHV-6, the impact of HHV-6 carriage in
these regions seems to be minimal. The presence of latent HHV-6 in the temporal region was
observed to have a positive effect on the rate of processing speed decline. As mentioned before,
this may have been an artifact of our relatively small sample size. Alternatively, there is a
possibility that the presence of HHV-6 may provide competitive pressure against other
pathogens or that the gene expression changes driven by HHV-6 might preserve certain
functional aspects of important cell units65, 104, 120. Also, there may be some kind of synergistic
relationship required for the development of AD that just isn’t present in these cases.
Essentially, HHV-6 may be present, but alone it might not have an effect. Assessing the
competitive/collaborative relationships between pathogens is already an extensive field of
study, but little has been found to suggest that HHV-6 is significantly limited or assisted by other
pathogens. Given its reservoir within certain immune cell populations, it is likely that it may
generate some kind of advantage for other pathogens, however.
Discussed previously, our NanoString results provided clear justification for my second
chapter via large observed changes in microglial, cytokine, and T-cell related gene pathways.
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Other studies have shown HHV-6 is capable of infecting microglia, but there has been little
examination of the effects of such an infection in the context of AD. Beyond that large overall
picture, we also observed considerable differences in terms of regional reactions to HHV-6. One
explanation for the differences in response to HHV-6 between the regions could be just an
overall difference in permissiveness to the virus. The cerebellum may just have fewer defense
mechanisms against viruses, which would make sense in the context of the antimicrobial
amyloid theory. Amyloid deposits are typically only observed in the cerebellum in the most
severe AD cases, and if we take amyloid deposition to be analogous to responses to pathogens,
our observed lack of reaction by the cerebellum appears to be the result of a lack of response to
the pathogen, rather than a lack of pathogen in the region. It is important to note that since we
were unable to quantify the viral load in these regions, there may be differences in the amount
of virus present in each region. The conserved genes between the regions predictably included
many genes related to innate immunity and autophagy65, 104, 120. In response to a viral infection,
these are typical responses to be expected65, 104, 120.
Overall, the first data chapter presented here largely demonstrated a lack of connection
between HHV-6 reactivation and rates of cognitive decline, as well as eventual consensus
diagnosis in the case of the autopsy cases. This is the first study to examine the connections
between even the presence of HHV-6, let alone markers of reactivation, and rates of decline in
separate cognitive domains. Previous studies have examined serological evidence of herpesvirus
reactivation and AD diagnosis. Our goal in trying to focus on cognition and the rates of decline
was to see if the reactivations were risk factors for more rapid disease progression that could
potentially help clinicians take more proactive measures in their treatment of those patients.
The fact that our results here are largely negative in nature suggests this effort is not
likely to be fruitful. Our work does suggest that further investigation of the interactions between
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different pathogens may be merited. If synergistic effects, such as those identified between
CMV, HHV-6, and HSV-1, can be teased apart and mechanistically understood, it would provide a
potential target for possible intervention.
This study also contributes to the ongoing controversy involving HHV-6 detection in
different studies61, 63, 64, 104, 130. Allnut et al. showed almost no HHV-6 in 2 much larger cohorts
than what we examined here63. Other studies have both refuted and supported Allnut et al., and
this study currently seems to refute their findings as well61, 63, 64, 104, 130. We found HHV-6 present
in a relatively high percentage of brain tissue that we examined. Others have suggested issues
with Allnut’s approach in terms of different DNA isolation protocols, which may have not
captured the relatively small viral genomes, resulting in their lack of positivity. The DNA
extraction protocol utilized here ensured viral genomic DNA would be captured.
The NanoString gene changes, again, drove us to the work presented in the second data
chapter. Microglial differences as a function of HHV-6 have not been previously reported in AD
cases, so such a finding would be significant, especially due to the importance of microglia
broadly in the study of AD. Other observed gene changes, namely the traditional innate immune
response pathways, were expected as a function of HHV-6 infection65, 104, 120. Our study approach
and size are significantly more constrained than Redhead et al. which showed connections
between HHV-6 gene expression and AD progression, but our NanoString data does support
some of the findings of that study61. The cytokine signaling and recruitment of T-cells in
response to HHV-6 is not necessarily novel, but in the context of how that recruitment might
contribute to AD, it is understudied55, 116.
Some limitations of this study are due to constraints present within the SBCoA cohort
inherently. For example, homogeneity of race in cases, frequency of blood draws, lack of
availability of certain brain regions, and limited amounts of certain samples were all limitations
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in this study. Ideally, blood draws would have been more frequent in order to capture a better
picture of reactivation frequency, but we only had access to the annual blood draws.
Additionally, access to cryopreserved buffy coat for these patients would have allowed an
investigation of T-cells from these patients to confirm HHV-6 reservoirs in that population and
possibly perform single cell level gene expression assays to assess effects of HHV-6 infection.

Data Chapter #2:
Few differences were observed in terms of microglial characteristics in autopsy tissue as
a function of HHV-6 presence. The increase in binary percent area in the presence of HHV-6 was
not accounted for by differences in activation in morphologies. So, we take this to indicate a
higher number of microglia in these cases. Given HHV-6’s tropism includes microglia, there
might be an increased susceptibility to HHV-6 infection in the presence of a higher density of
microglia. It is also possible that HHV-6 is present below our detection threshold in the other
cases, possibly due, in part, to a lower number of microglia carrying HHV-6 in those cases. While
we observed some differences between E4 and wild type microglia in terms of phagocytic
capacity, HHV-6 infection seemed to have minimal impact on the same functionality within any
genotype. At the very least, we did expect free floating virus in the solution to induce some
amount of enhanced phagocytic activity in the microglia, but we didn’t observe even this. ApoE
is primarily produced by astrocytes in the brain, so their exclusion from the culture may have
reduced any potential effects we could have expected to observe.
Since HHV-6’s tropism includes astrocytes as well, it is possible that the meaningful
infection is in the astrocytes and the microglial gene changes we observed in the autopsy tissue
were downstream results of astrocyte level changes. Or potentially other cell types, such as Tcells, carrying HHV-6 are driving the differences in a similar way. The focus on the microglial
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level was, in hindsight, likely myopic and overly simplistic. Further examination of HHV-6
mediated gene changes related to neuroinflammation will certainly require more
comprehensive models.
We observed evidence of T-cells both surrounding and within amyloid beta plaques in
our autopsy cases, suggesting T-cells were being recruited to help resolve plaques, but, in some
cases, were also carrying HHV-6 into the CNS. Overall, we observed that this was a relatively
minor occurrence, with most T-cells identified in proximity of plaques being around the plaque,
rather than within. The involvement of T-cells, or any other peripheral immune components, in
the infectious hypothesis has not been examined beyond routes of entry into the CNS.
In the case of HHV-6, T-cell recruitment ends up being a bit of a double-edged sword,
though our other results suggest that HHV-6’s presence may be generating little effect anyways.
T-cells may help resolve brain injury or insult, but extended periods of inflammation can be
damaging, and the introduction of HHV-6 could cause infection on top of existing damage. The
larger implication is the potential involvement of T-cells in the infectious hypothesis may be
more important than previously expected. Previous research has shown that T-cells, or rather a
lack or dysfunction of them, may already contribute to AD pathology137-140. If viral infection is
affecting recruitment, this might then compound the effects. The lack of viable buffy coat for
potential experiments mentioned above is particularly frustrating in this case, as an examination
of the differences in the T-cells in these patients could have potentially tied in already observed
characteristics of myeloid cells in AD. However, this does represent an avenue for future study.
Though we did observe some plaques with HHV-6 present, the vast majority of plaques
observed did not have HHV-6 present. This finding is not unforeseen, since HHV-6 likely
represents a minority of the pathogens, or non-pathogenic amyloid aggregating seeds, present
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in any given patient. The fact we saw at least some present in plaques does confirm that HHV-6
is capable of seeding plaques in the brain and not just in culture or in animal models59, 141.
HHV-6’s effects on microglia have been previously observed in a limited fashion65, 73, 76.
This study is the first to examine morphological and functional differences in microglia due to
HHV-6 in the tissue of AD patients. While the results were largely negative, we have shown that
the focus of future work on HHV-6 in this context should be on different cell types, possibly
astrocytes and T-cells. The lack of phagocytic differences is surprising, but also adds to the body
of knowledge of what aspects of microglial function are altered, or not, by HHV-6.
Finally, we are the first to examine the differences in T-cell distribution as a function of
HHV-6. While the results were negative and showed a predictable recruitment of T-cells to assist
with the resolution of plaques, it does suggest that T-cell functionality within the brain in the
context of infection may be of potential importance. Generally, crosstalk between the periphery
and the CNS is often overlooked, and that has been the case largely with the infectious
hypothesis. So many studies have focused on how and if certain viruses were in the brain, while
disregarding what effects they could be exerting from the periphery or the responses they might
elicit from the periphery91, 96, 98, 135, 142-144. Further examination of peripheral and CNS interaction
in the context of the infectious hypothesis is merited.

Limitations:
The limitations of Aim 1 have primarily to do with our ability to measure reactivation of
HHV-6 specifically. The use of proxy reactivations in the survey can give us some insight into
HHV-6’s reactivations, but it still is not a measure of HHV-6 reactivation. Further, our
quantification within the brains of the patients was not a measure of reactivation directly either,
instead identifying, more so, the presence of latent HHV-6. This study also makes the
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assumption that reactivation in the periphery is indicative of a reactivation within the brain. It is
not fully understood how the dynamics of reactivation are changed when in the brain.
One could argue that a notable limitation of this study is the lack of quantification of
viral load using ddPCR. Our sample integrity was, overall, fairly low, and we did not feel
comfortable trying to report concentration values that we knew could be wildly inaccurate.
Additionally, the focus on viral load in very narrowly constrained regions is largely pointless.
Millimeter to millimeter differences in location could result in huge differences in viral load
within a region. Viral genomes are not a diffuse signaling molecule that distributes evenly within
a region or even in a convenient gradient. A cluster of cells might all be infected, but the ones
next to them uninfected. The viral load result is dramatically different if all, some, or none of the
cluster is included in the tissue being used. At least by limiting ourselves to presence, we
minimize the potential for misleading results of this kind. The most effective approach would be
whole region bulk sequencing, but given the multiple different demands for this tissue, this just
is not a viable option.
Verification of shingles vaccine usage in our self-reported measures would have been
valuable as well. While we can make an educated assumption that the low incidence of shingles
compared to chicken pox is due to the vaccine, verification of this would help to solidify one of
the few significant findings from the self-reported data.
As is the case with many studies such as this, the sample size is a limiting factor. To
properly account for the effects of age, sex, education, ApoE genotype, and other common AD
factors, we would need an incredible number of patients to properly power this study. The fact
that we do see some significant differences is exciting. Expanding the sample size of a study like
this would always be a boon, however, we were still able to make some findings to motivate
future studies.
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The largest conceptual limitation of this study is likely the inherent assumption that
reactivations late in life are the most important in how HHV-6 could be driving AD. Our
population is notably elderly, as it comes from an ADRC, so that is what we have available. But
studies have shown HHV-6 infection of the cerebellum in childhood can have an impact on
mood and behavior disorders later in life136. This study assumes that reactivations in old age are
the critical ones, but there is a distinct possibility that the virus could be exerting its influence
much earlier in life, potentially in development. Even if HHV-6 doesn’t impact development,
damage from reactivations may be cumulative in nature, and this study does not come close to
capturing the whole picture of HHV-6 infection and reactivation in these individuals. No current
studies are capturing significant timeframes of HHV-6 reactivation, but an expansion of our
existing timeframes is likely needed in order to determine when critical periods in the HHV-6 life
cycle are occurring.
Our cognitive analysis was the final limitation of Aim 1, as it was likely an
oversimplification of the cognitive progression of the patients. Inclusion of all cognitive data
points introduced a bias that artificially minimized the slopes of patients present in the cohort
longer. For example, if a patient had been followed for 10 years and experienced a dramatic
decline from year 6 to 7 our analysis would yield a slope far closer to 0 than a patient who had
been seen for only 2 years but experienced an identical decline between those years. Therefore,
our analysis is too broad in its scope and future iterations will focus on the data points relevant
to the cognitive decline.
There were a number of limitations with Aim 2 as well. Some were
straightforward, such as our lack of a secondary microglial marker to verify the IBA-1 findings.
We attempted to replicate various previously reported staining protocols using P2RY12 but were
unsuccessful106. This may have been due to the paraffin embedded nature of our tissue, though
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other studies present successful staining using this tissue. Additionally, as with the first chapter,
sample size is always a limitation when working with autopsy cases such as these.
As I mentioned above, the phagocytosis assay may have been too simplistic as a
monoculture. Even a co-culture with astrocytes could have yielded more biologically significant
findings as it pertains to ApoE’s effect with HHV-6. We also would have liked to verify the results
we observed via traditional imaging using a flow-cytometry-based approach145. Essentially, we
would have liked to perform the same infection and phagocytosis, but then suspended the cells
in solution and used flow-cytometry to quantify the cells that had taken up the beads. Our use
of fluorescent latex beads may also have influenced the results since amyloid is detected via
specific receptors on the microglia26, 27, 29, 146, 147. Debris, which the beads would have been
detected as, is detected by more general receptors26, 27, 29, 146, 147. It is possible this difference
resulted in a response different from what we had expected. We used the beads on the advice
of multiple sources that indicated inconsistent oligomerization of synthetic amyloid beta made it
very difficult to use in an experiment such as this. Further, our staining of HHV-6 in the cultures
during optimization of the model did not necessarily mean that the virus was effectively
infecting and incorporating into the host microglia. In order to properly assess this, we would
need to perform an in situ hybridization assay for the viral genome in order to determine its
integration into the host genome.
Additionally, the tissues used throughout the study’s staining experiments were paraffin
embedded. This was a problem nowhere more than in terms of the fluorescent staining. Ideally,
we would have stained for amyloid, T-cells, and HHV-6 all on the same piece of tissue in order to
examine their colocalization comprehensively. However, we had considerable issues with our
established immunostaining protocols for amyloid, forcing us to use Congo as an alternative148.
This unfortunately generated background signal in other channels that made imaging more
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difficult. Additionally, the high background inherent in paraffinized human tissue made it
difficult to use one fluorescent channel for HHV-6 or T-cells without using the other to cancel
out background signal149. (i.e. Leaving one channel unoccupied in order to cancel background in
the channel used for the stain in question.)

Summary and Context:
This extended study has investigated the influence of HHV-6 on the progression of AD,
specifically how HHV-6 reactivation influences cognitive decline and how HHV-6 infection alters
microglial function and related recruitment of T-cells. The lack of association between markers
of reactivation and cognitive decline matches what others have observed in the cases of other
non-HSV1 herpesviruses71, 72. This study, however, is the first to examine specific cognitive
domain decline rather than overall risk of AD or specific pathological markers. The lack of
association between the latent HHV-6 and Braak & CERAD staging contributes to the already
conflicting literature that has examined HHV-6 in similar contexts62, 63, 74, 104, 130. Multiple studies
have found no association with pathologies, while other have not only found associations, but
have isolated HHV-6 from amyloid plaques62, 63, 74, 104, 130.
The alterations of microglial gene expression observed as a function of the presence of
HHV-6 presented a secondary focus: if not the amyloid plaques themselves, then could the cells
responsible for resolving them be the interaction point for HHV-6? It is already known that HHV6 can infect microglia, as well as astrocytes, but little is published on how this alters their
functions relevant to AD75, 116. It’s possible this is due to negative findings not being previously
reported, especially since most of what we observed about HHV-6’s influence on microglia was
ineffectual in nature. While disappointing in the context of this study, it does not mean HHV-6 is
not contributing in some way to AD progression. For one, this study did not examine astrocytes
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and their alterations under HHV-6 infectious conditions. Secondly, we did observe gene changes
related to the recruitment of T-cells from the periphery in infected cases.
There is a considerable amount of work being done on the potential involvement of Tcells in AD. Overall, literature seems to suggest that involvement of T-cells in resolution of CNS
injury or insult is beneficial to the health and wellbeing of the brain138, 139. Further, T-cell
depletion from other causes, such as chemotherapy and HIV infection, are associated with
cognitive impairments as AD is150. However, T-cells are like microglia in their capacity for
damaging effects when present for extended periods of time, meaning they too have a complex
role that cannot be oversimplified137, 138. HHV-6’s role in altering T-cell recruitment to the brain
or subsequent function therein has not been studied beyond what we have observed here, but
merits future examination.
Overall, this study has provided support for shifting the focus of HHV-6’s role in AD away
from plaques and microglia, and toward other potential mediators of the disease like T-cells and
astrocytes. We present novel work in examining the effect of a herpesvirus species on specific
cognitive domain decline that can hopefully be built upon in the event that lengthier
longitudinal studies are performed with pathogens in mind. We also present novel information
about how HHV-6 effects microglia under aged physiological conditions, or rather how it does
not. From a basic science perspective, this widens our understanding of HHV-6 infections and
how they affect us. Finally, we showed a connections specifically to T-cells and their
recruitment, connecting HHV-6 to another extensive field of study in regards to AD.
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Future Directions:
While the results of this study were primarily negative, they do present some interesting
avenues for future study. The most obvious of which is leveraging developing technologies to
better assess the effects of HHV-6 at the cellular level. Microdissection and single cell level
assays would enable a more detailed understanding of how HHV-6 is changing the function of
microglia or astrocytes in these aged cases.
One of the major weaknesses I mentioned in chapter 1 was the assumption that the
reactivations observed in old age were the most impactful reactivations. Future studies could
look at younger cohorts to expand our understanding of the impact of timing and/or frequency
of reactivations. Another potential option would be periodic examinations of individuals already
studied at a young age in HHV-6 related studies. If a prior study has already observed some
individuals have HHV-6 present in their cerebellum, follow up studies with these patients at a
later age could then try to draw connections between changes in cognition or the development
of dementias with findings from much earlier time points. Lifelong studies of populations are
expensive and difficult, so leveraging existing populations may be the best approach. We may
just need to expand our consideration of populations.
The development of 3-dimensional organoids has proven to be a boon for a number of
fields since they better simulate the physiology of cells and organs in culture than mono- or cocultures ever could. Inducing HHV-6 infection in brain organoids and then sorting out different
cell types to assess rates of infection and differential responses under different conditions
would be a huge avenue for future research.
This study’s focus on HHV-6 alone was unfortunately a shortcoming. Other studies had
demonstrated that, 1) other pathogens have been implicated in AD for far longer than HHV-6
and 2) there seem to be synergistic effects between some pathogens72, 102. A more
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comprehensive examination of how HHV-6 interacts with other pathogens would be valuable in
understanding the potential sequelae of events leading to potential pathology in AD. Does HHV6 prime the reactivation of other viruses? Is it in direct competition with other viruses?
Examining the temporal aspects of reactivation in the context of other pathogens would be a
valuable path forward as well.
Finally, there is always a potential value in animal models. Studies have already shown
that repeated reactivation of HSV-1 in an animal model of AD generated more rapid
accumulation of amyloid plaques and more rapid cognitive decline98. A similar study using
murine roseola virus, the mouse equivalent of HHV-6, could be carried out. A recent study
showed that carriage of murine roseola virus did not significantly alter progression in an AD
animal model, but the study involved only one infection timepoint and no attempts to quantify,
let alone control, the number of potential reactivations151.
Alternatively, the overall lack of associations between HHV-6 and the cognitive and
pathological outcomes could merit a shift toward the more neurotropic herpesviruses that have
more considerable evidence of involvement in AD. HSV1 and VZV both have been implicated in
AD and both more frequently than HHV-6. Taking this a step further, the majority of significant
results observed in this study have to do with modulation of inflammation. At the most simple
level, HHV-6 are a source, and potentially a modulator, of inflammation when present in the
brain. Future studies could focus on how downstream inflammation, generated through antiviral detection and response, contribute to AD. Specifically, examining how toll-like receptor
signaling and downstream interferon flux alters responses to pathology and the health of the
cells in proximity to pathology. Knockout and constitutive over-expression/activation models of
numerous toll-like receptors and interferons exist and provide a wide range of tools to focus
more on the downstream effects of these viruses, rather than the viruses themselves.
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Ultimately, this research takes a number of novel steps in assessing the potential role of
HHV-6 in the development of AD. We are the first to examine the effects of herpesvirus
reactivation on the rate of decline in various cognitive domains, assess the specific impact of
HHV-6 reactivation on cognition, examine the impact of HHV-6 infection on the characteristics
of microglia within an AD context, and the first to examine HHV-6 and ApoE’s combined effect
on microglial phagocytosis. Our other results add to the body of evidence in the ongoing
discussion over what role, if any, HHV-6 might be playing in AD. This study provides another
building block to our understanding of AD and its potential infectious etiology.
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Abstract:
Vascular contributions to cognitive impairment and dementia (VCID) are the second leading
cause of dementia behind Alzheimer’s disease. Apolipoprotein E (ApoE) is a lipid transporting
lipoprotein found within the brain and periphery. The APOE e4 allele is the strongest genetic risk
factor for late onset Alzheimer’s disease and is a risk factor for VCID. Our lab has previously
utilized a dietary model of hyperhomocysteinemia (HHcy) to induce VCID pathology and
cognitive deficits in mice. This diet induces perivascular inflammation through cumulative
oxidative damage leading to glial mediated inflammation and blood brain barrier breakdown.
Here, we examine the impact of ApoE e4 compared to e3 alleles on the progression of VCID
pathology and inflammation in our dietary model of HHcy. We report a significant resistance to
HHcy induction in e4 mice, accompanied by a number of related differences related to Hcy
metabolism and methylation cycle, or 1-C, metabolites. There were also significant differences
in inflammatory profiles between e3 and e4 mice, as well as significant reduction in Serpina3n, a
serine protease inhibitor associated with ApoE e4, expression in e4 HHcy mice relative to e4
controls. Finally, we find evidence of pervasive sex differences within both genotypes in
response to HHcy induction.

Keywords: APOE; VCID; inflammation; metabolism; SERPIN
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Introduction:
Vascular contributions to cognitive impairment and dementia (VCID) are the second
leading cause of dementia behind Alzheimer’s disease (AD) 152. Our lab has previously
demonstrated a dietary animal model of VCID via induction of hyperhomocysteinemia (HHcy),
an established independent risk factor for stroke and VCID 107, 153. The diet acts by eliminating
vitamins B6, B12, and folate, while elevating methionine, in order to drive the production of
homocysteine (Hcy) 154. Use of this diet has been shown to generate cognitive impairment,
hemorrhagic vascular pathology, and gliosis in wild type mice 107, 154. The Hcy dietary model of
VCID is thought to exert pathology by way of endothelial oxidative stress, initiating a sequelae of
events including inflammation, upregulation of matrix-metalloproteinases, degradation of the
basement membranes and tight junctions of the vasculature, ultimately resulting in blood-brain
barrier breakdown and astrocytic end-foot dissociation, microhemorrhages, and cognitive
impairment 107, 133, 153.
Apolipoprotein E (ApoE) is a lipid binding protein involved primarily in the binding and
transport of cholesterol within the brain and periphery 77. The e4 allele of APOE is most
commonly known as the strongest genetic risk factor for developing late onset AD 77, 155.
However, it has also been identified as a risk factor for VCID

156-158

. Recent research also

suggests APOE alleles have a significant impact on neuroinflammation 90, 95, 159. Despite the
connection between ApoE and VCID risk, the mechanism by which it contributes to disease
progression has not been definitively established. While some research has shown that ApoE
exerts some level of anti-oxidative functionality 160, 161, with e2 being most effective and e4 being
least effective, APOE allele differences have not been assessed as modulators of oxidative
damage induced vascular pathology.
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In the current study, we examine the impact of ApoE e3 and ApoE e4 homozygous
carriage on HHcy-induced VCID using a humanized ApoE mouse model in conjunction with a
dietary HHcy model. We find that e3 mice developed more severe levels of HHcy than e4s, along
with significant differences in methylation metabolites involved in the HHcy cycle. Further, there
was significant inflammatory differences between the two genotypes, with e3s presenting with
higher levels of neuroinflammatory cytokines than e4s, namely, IL1b and members of the matrix
metalloprotease systems. Contrary to our hypothesis at the outset, the e4 mice presented with
fewer instances of hemorrhagic vascular pathology than their e3 counterparts. We also show
significant increases in the expression of APOE and SERPINA3N in e4 mice reared on a HHcy diet
in a sex dependent manner. Finally, we show substantial sex differences within genotypes in
response to the HHcy diet in most experimental endpoints presented here, suggesting an
interaction between sex and APOE genotype in the progression of VCID.

Methods & Reagents:
Mouse Husbandry:
Human ApoE 3/3 and 4/4 homozygote knock-in mice as described previously were used for this
study 122, 123. Groups are laid out in Table 1. Mice were bred in house and housed in groups of 24 typically, with only 3 mice being singly housed. Mice were aged to approximately 6 months old
before administering respective diets. The study was approved by the University of Kentucky
Institutional Animal Care and Use Committee and conformed to the National Institutes of Health
Guide for the Care and Use of Animals in Research. All studies were performed blinded. All
studies were completed in compliance with the Animal Research: Reporting In Vivo Experiments
guidelines. Sample sizes were based on power analyses performed for previous papers involving
mice on the HHcy diet 124, 125.
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Diet Administration:
Mice were given either the HHcy diet (Envigo TD130867; Indianapolis, IN) which is deficient in
vitamins B12, B6 and folate and enriched in methionine, or a nutritionally corrected Control diet
(Envigo TD01636) ad libitum. Animals were weighed weekly to monitor body mass loss and any
forms of ailments. Diet was administered for 12 weeks, at which point animals were euthanized
and tissue collected.
Tissue Collection and Processing:
Animals were euthanized and tissue collected as previously described 107. Briefly, animals
received a lethal intraperitoneal injection of beuthanasia-D. When animals were unresponsive
to footpad and tail stimulation, animals were then intracardially perfused with 20mL normal
saline. Blood was collected at euthanasia prior to perfusion and spun at 1000xg at 4 degrees for
15 minutes and plasma collected. Brain was removed for further dissection. The right
hemisphere was dissected into frontal cortex, posterior cortex, hippocampus, striatum,
cerebellum, thalamus, and the remainder of midbrain and flash frozen in liquid nitrogen and
stored at –80oC until performance of studies. The left hemisphere was placed into freshly
prepared 4% paraformaldehyde for 24 hours. The left hemispheres were passed through a
gradient of 10% and 20% sucrose for 24 hours each and 30% sucrose for 48 hours for
cryoprotection. Tissue was sectioned horizontally at a thickness of 25µm serially using a sliding
microtome with a freezing stage. Sections were stored at 4°C in a 1xPBS solution containing
sodium azide (0.82g in 1L).
RNA Extraction:
Frozen right hippocampi were extracted for RNA as previously described (Sudduth et al., 2017).
Briefly, tissue was homogenized via rotor homogenization and then RNA was extracted using the
E.Z.N.A. Total RNA Kit (Omega Bio-Tek, Norcross, GA) according to manufacturer’s instructions.
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Aliquots of the RNA were sent to the UK College of Medicine Genomics Core for concentration
and RNA integrity determination using an Agilent 2100 Bioanalyzer.
NanoString:
Aliquots of 10µL of 10ng/µL RNA were prepared and ran on the NanoString SPRINT system using
the NanoString Mouse Neuroinflammatory Panel kit by the UK College of Medicine Genomics
core. Data was returned to experimenters in the form of spreadsheets containing raw counts for
each of the included targets.
Gene expression for all endogenous genes was investigated using multivariable linear regression
models (Gene Expression Data Analysis Guidelines. Nanostring Technologies. 2017). Transcript
counts for each gene were regressed on the sum of all positive control gene counts (for
normalization), and an indicator for: diet (HHcy diet or control diet), genotype (e3 or e4), or sex
(male or female). Since gene expression counts were expected to be right-skewed, gene
expression counts and the sum of all positive control gene counts were log-transformed (base 2)
prior to modeling (nCounter Advanced Analysis 2.0 Plugin for nSolver Software. NanoString
Technologies, 2018). The differential expression p-values for diet, genotype, and sex were
adjusted using an FDR cutoff of 0.05 and converted to q-values.
All analyses were performed in R version 4.0.3 (R Core Team (2020), Vienna, Austria).
cDNA Preparation:
RNA from the right hippocampus was also used to generate cDNA as previously described
(Sudduth et al., 2017). Briefly, the High Capacity cDNA Kit (ThermoFisher, Grand Island, NY) was
used to generate cDNA at a concentration of 50ng/µL and then stored at -20°C in preparation
for RT-qPCR.
RT-qPCR:
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RT-qPCR was performed for the probes listed in Table 2 as previously described (Sudduth et al,
2017). Briefly, 1µL of cDNA was diluted with 6µL of RNase-free water and then added to a mix of
1µL of the respective probe and 10µL of FastTaq. Target amplification was achieved using the
ViiA7 (Applied Biosystems, Grand Island, NY). Results were collected as Comparative CT relative
to 18s rRNA, used as our endogenous control. Fold change was calculated for each sample based
on -DDCT calculations (Livak and Schmittgen, 2001). Grubbs outlier test was applied to each
group prior to analysis. Samples that were identified as statistical outliers were removed from
further analysis of that particular measure. ANOVA and each-way t-tests were performed
between groups for each target using JMP Statistical Software (JMP Pro 13). Group averages and
standard error of the mean were then plotted using GraphPad Prism 9.
Tissue Histology:
7-8 sections spaced 600µm apart were utilized for all staining protocols.
Prussian Blue Staining: Sections were mounted onto slides and dried overnight before 30 second
rehydration in distilled water. This is followed by a 30-minute incubation in a solution of 2mL
concentrated HCl, 198mL water, and 2g potassium ferrocyanide mixed immediately before use.
Slides are then washed for 5 minutes in distilled water twice, and tap water once. Slides were
then incubated for 5 minutes in neutral red (Sigma Aldrich, St. Louis, MO). Slides rinsed 3 times
for 1 minute in tap water. Slides dipped momentarily in 95% ethanol, ensuring that neutral red
staining is not lost. This is followed by another quick dip into 100% ethanol. Slides then went
through two 5-minute xylene incubations prior to cover-slipping using DPX Mounting Media and
VWR Micro Cover Glass (VWR, Radnor, PA). Slides were then imaged at 20x using the Zeiss
AxioScan. Images were then transferred to the HALO Image Analysis software in order to detect
potential microhemorrhages in the form of positive Prussian blue staining. The blinded
experimenter then examined each potential microhemorrhage to determine whether it was an
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artifact or a true microhemorrhage. Briefly, the staining had to be associated with a vessel, had
to be in the same focal plane as the tissue, and could not contain any obvious instances of
artifacts. Multiple bleeds associated with a segment of blood vessel were counted as an
individual microhemorrhage. Once artifacts had been removed, the number and area of
microhemorrhages for each group were analyzed. First, statistical outliers were removed using
the Grubbs’ Outlier test. ANOVA and each-way student’s t-tests were then performed between
each group using JMP Statistical Software (JMP Pro 13). Group averages and standard error of
the mean were then plotted using GraphPad Prism 9.
Immunohistochemistry Staining: Immunohistochemistry for IBA-1 (Wako/Fuji Film cat#01919741, Richmond Virginia), GFAP (Agilent, DAKO Cat# Z033401, Santa Clara, CA), and albumin
(Bethyl, Cat#A90-234A, Montgomery, TX) were performed in the following manner. Tissue was
placed into PBS before being washed with a methanol solution (10% methanol, 3% hydrogen
peroxide, PBS) for 15 minutes. Following the methanol solution, the tissue was washed 3 times
in a PBS and 4% goat serum solution and then placed into a blocking solution (0.2% triton-X, 4%
goat serum, 0.0019% L-lysine in PBS) for 30 minutes. The sections were then transferred into a
primary antibody solution (4% goat serum, PBS, respective ratio of primary antibody: IBA-1
(1:1,000), GFAP (1:10,000), Albumin (1:10,000)) for one hour at room temperature and then to
4°C overnight. The following day, the sections were placed at room temperature for one hour
before washing three times in PBS and 4% goat serum for five minutes each. Sections were then
transferred to a secondary antibody solution ((4% goat serum, PBS, respective amount of
secondary antibody: IBA-1 – anti-rabbit (1:3,000), GFAP – anti-rabbit (1:5,000), Albumin – antigoat (1:5,000)) for two hours, followed by another set of washes. Sections were then treated for
one hour with an ABC solution (Vectastain Elite ABC Kit, Vector Laboratories, Burlingame, CA)
consisting of 1 drop of each reagent A&B to 10mL of PBS. Following another set of washes, the
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sections were then transferred into a DAB solution kit (ImmPACT DAB EqV Kit, Vector
Laboratories, Burlingame, CA for albumin & DAB Kit w/ nickel [SK4100], Vector Laboratories,
Burlingame, CA for IBA-1 and GFAP) consisting of a 1:1 ratio of reagents A and B for a respective
amount of time (IBA-1 – 26 seconds, GFAP – 30 seconds, Albumin – 19 seconds). Sections were
washed another three times and then mounted onto slides and cover-slipped as described
above. Slides were imaged on the Zeiss Axio Slide Scanner as described above and the images
transferred to the HALO Image Analysis software for further analysis. Two analyses were run for
the IBA-1 staining: a binary percent area analysis for positive IBA-1 staining and a microglial
activation analysis. The microglial activation analysis suite from HALO Image Analysis uses
morphology in order to assess activation status of microglia, based on number of processes and
their length. Statistical outliers were removed using the Grubbs’ Outlier test. ANOVA and eachway student’s t-tests were then performed between each group using JMP Statistical Software
(JMP Pro 13). Group averages and standard error of the mean were then plotted using
GraphPad Prism 9.
tHcy and Methylation Metabolite Mass Spectrometry:
Plasma and brain tissue total homocysteine (tHcy) was determined by liquid chromatography
electrospray positive ionization tandem mass spectrometry (LC-ESI-MS/MS) as previously
described 162. Brain tissue was processed using a modified technique to extract protein-bound
HCY. The tissue was homogenized in 4 vol of 5 mM DTT and 10 µM 2H4-HCY and incubated on ice
for 20 min. The homogenized samples were centrifuged at 14,000 rpm at 4°C for 10 min.
Aqueous supernatant was transferred to a 10,000 MW cutoff filter unit and centrifuged at
14,000 rpm at 4°C for 25 min. The filtered extract was directly injected in the LC-MS/MS system.
Plasma and tissue methylation metabolites (SAM, SAH, methionine, cystathionine, choline and
betaine) were determined by LC-ESI-MS/MS 163, 164 as previously described. For plasma, 20 µL

108

was added to 180 µl of isotope internal standards and loaded into a microtiter plate before
being centrifuged for 60 min prior to analysis. For methylation metabolites in brain tissue,
samples were deproteinized with 4 volumes of 0.1M perchloric acid. After centrifugation, brain
extracts were diluted 1:10 with the LC mobile phase containing 5–25 µM labeled-isotope
internal standards. Two levels of quality control samples were used to monitor precision of the
method. In all cases the coefficient of variation was less than 10% for all metabolites.
Normality tests:
Normality of each data set was assessed via visual inspection and application of the ShapiroWilks test for normality using JMP. Non-parametric data sets were analyzed using Wilcoxon
tests, as opposed to t-tests for parametric data sets. Appropriate adjustments to figures
containing non-parametric data is reported in each figure legend.

Results:
ApoE Genotype Modulates tHcy Levels and Accompanying 1-C Metabolites:
Plasma Metabolites:
Administration of the Hcy diet led to significantly higher levels of plasma Hcy in the e3
mice compared to e3 Control and was even significantly higher compared to the e4 Hcy group.
The e4 Hcy group had elevated plasma Hcy compared to e4 Control (Fig. 1b). Methylation
metabolites involved in the Hcy cycle were also measured. Choline, methionine, and Sadenosylhomocysteine (SAH) were not significantly different at the group level (Supp. Figure 1d,
1c, & 1b). Plasma S-adenosyl methionine (SAM) was significantly lower in the e4 Control group
relative to the e4 HHcy group, while the e3 HHcy and control groups showed no significant
difference to one another (Supp. Figure 1a). Cystathionine was significantly elevated in e3 HHcy
group relative to e3 control and the e4 HHcy group (Fig. 1c). Betaine was also significantly
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different between all groups, with controls having higher levels than groups on the HHcy diet
(Fig. 1d). We observed sex differences in the e3 HHcy group, with males having higher levels of
cystathionine (Fig. 1f). Additionally, the female e3 HHcy and control female e4 groups had a
higher SAM/SAH ratio than male counterparts (Supp. Figure 2e). SAM is a global methyl donor,
while SAH acts as an inhibitor of SAM methyl donation. Therefore, the ratio of the two
metabolites provides insight into methylation capacity via SAM.
Tissue Metabolites:
Midbrain tissue was also analyzed for levels of tHcy and related methylation
metabolites. This area was the only region consistently with enough tissue for mass
spectrometry experiments. We observed no difference in the level of tHcy between groups
(Figure 2a). Cystathionine levels were significantly elevated in the e3 HHcy group over all other
groups (Fig. 2b), as was the case with SAH (Fig. 2d). Differences were also observed in betaine
(Fig. 2c) and SAM (Fig. 2e) levels. Importantly, there was a significant reduction of the SAM/SAH
ratio in the e3 HHcy group relative to all other groups, suggesting a limited methylation capacity
(Fig. 2f).
Sex differences were observed in the levels of SAM (Fig. 3c) in the e4 Hcy group, with
the females having higher levels compared to male counterparts. There were no statistically
significant differences observed in terms of total Hcy levels (Fig. 3a) or SAM/SAH ratio (Fig. 3e) in
the midbrain between sexes of any group.
e3 Mice Showed Higher Incidence of Cortical Vascular Pathology:
Prussian blue staining indicated an increase in cortical microhemorrhages in the e3 Hcy
groups relative to each of the control groups. The e4 HHcy group showed no difference
compared to e4 control group (Fig. 4A). No significant differences, at the group level, were
observed in the number of hippocampal bleeds (Fig. 4B). Sex differences were observed in the
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e3 HHcy group, with males presenting with significantly larger cortical bleed areas (Supp. Fig.
7c). Hippocampal microhemorrhages were not observed in female mice with the exception of
the e4 HHcy group (Supp. Fig. 7b). Additionally, male e4 control mice had significantly more
hippocampal microhemorrhages than the e4 HHcy or e3 control groups (Supp. Fig. 7b). No sex
differences were observed in terms of hippocampal bleed area (Supp. Fig. 7c).
e4 Mice Exhibited Atypical MMP & TIMP Modulation in Response to HHcy Induction:
Expression of MMP3 was not significantly different between groups, even when
accounting for sex (Supp. Fig. 4 a & d). Expression of TIMP1 was elevated in e4 HHcy over e3
controls (Supp. Fig. 4b). Expression of MMP9, which our lab has previously shown to contribute
to the development of vascular pathology, was elevated in the e4 HHcy group, relative to the e3
control group. The e3 HHcy and e4 control groups were not significantly different (Fig. 5c).
MMP14 was elevated in e3 HHcy over control, with no differences between e4 groups (Fig.5g).
MMP2 was elevated in both the e3 HHcy and e4 control groups over e3 control (Fig. 5b). Finally,
TIMP2 expression in e4 controls being significantly higher than e3 controls (Fig. 5a).
No sex differences were observed in the e3 HHcy group in terms of MMP2 levels (Fig.
5e), MMP9 (Fig. 5f), or TIMP2 (Fig. 5d). MMP14 expression in e3 HHcy mice was elevated over
control counter parts (Supp. Fig. 4c).
Microglial Activation in the Hippocampus was Elevated in e3 HHcy Mice Compared toe4:
No significant differences were observed in terms of frontal cortical IBA-1 staining area
(Fig. 6a). The percentage of microglia activated, as determined by morphology, in the frontal
cortex was significantly higher in e3 HHcy over control counterparts (Fig. 6c). No differences
were observed in IBA-1 staining area in the hippocampus, suggesting there were not a
significantly different number of microglia or issues related to proper microglial maturation (Fig.
6b). A significant increase in microglial activation in the hippocampus was observed in e3 HHcy
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relative to e4 HHcy, suggesting the microglia of the e4 mice were less responsive to the dietinduced inflammation (Fig. 6d).
No sex differences were observed in terms of frontal cortical microglial activation (Supp.
Fig. 8c). However, differences were observed in terms of IBA-1 staining area between e4 HHcy
and control males and females in both the frontal cortex and just the e4 HHcy group in the
hippocampus (Supp. Fig. 8a & b). e4 control males showed higher hippocampal microglial
activation compared to female counterparts (Supp. Fig. 8d).
Astrogliosis Influenced by Sex, not Genotype Independently:
No group level differences in GFAP area were observed (Supp. Fig. 9a), though sex
differences were present in the e3 HHcy group, with males presenting with greater levels of
GFAP staining relative to female counterparts (Supp. Fig. 9b). This suggests elevated levels of
astrogliosis in these males.
Serine Protease Inhibitor Serpina3n Highly Differentially Regulated:
Analysis of NanoString Panel results revealed a sparse number of family-wise significant
differentially expressed genes after false discovery rate correction. All nominally significant
genes (p-value< 0.05) are shown along with their respective effect sizes and q-values (Table 3-7).
The two genes with a q-value below a cut-off of 0.05 were Rps9 and Serpina3n, both of which
were differentially expressed between e3 Control and e4 Control groups (Table 3). Rps9 encodes
a ribosomal subunit protein 165. Serpina3n encodes a serine protease inhibitor, also known as
alpha 1-antichymotrypsin 166. Previous literature has shown that Serpin family genes are
elevated in e4 homozygous mice 146.
Key Control Inflammatory Gene Expression Differences Observed in Addition to Strong Sex
Differences:

112

qPCR results showed no significant group level differences in expression of IL1RN (Supp.
Fig. 5b), CD86 (Fig. 7a), or TNFa (Fig. 7c). IL1b expression was elevated in e3 HHcy over control
counterparts (Fig. 7b). Some sex differences were observed in these genes as well. Namely,
TNFa was elevated in e3 control females over male counterparts (Supp. Fig. 6e) and IL1rn was
significantly elevated in e4 control females over males (Supp. Fig. 6c).
A number of additional genes were also measured via RT-qPCR, including APOE and
TREM2, as well as a number of genes identified in the NanoString analyses. Hippocampal
expression of ApoE was not significantly different between any groups (Fig. 7d). ARC
hippocampal expression was elevated in the e4 HHcy group over e3 HHcy and e3 controls (Fig.
7e). SERPINA3N expression was elevated in a genotype dependent manner, with expression in
the e4 groups being significantly higher than e3 groups (Fig. 7f). No significant differences were
observed in expression of FOS (Supp. Fig 5d), NTHL1 (Supp. Fig 5f), and TREM2 (Supp. Fig. 5g).
We did observe a significantly greater level of expression of BCAS1 in e4 controls over e3
controls (Supp. Fig. 5c). Sex differences were observed in SERPINA3N expression, with male e4
HHcy mice expressing greater levels than female controls (Fig. 7 h).

Discussion:
In this study we observed a limitation in the induction of HHcy in the e4 group.
Accompanying this, we also observe less vascular pathology in the e4 HHcy group. While it is
possible that the downstream differences we observed can be explained by a difference in the
severity of HHcy, we believe this is at most only partially true, as we observe a number of
baseline differences between e3 and e4 controls that suggest underlying differences
independent of HHcy severity. In particular, the elevation of select TIMPs and MMPs contradicts
this idea, as the e4 controls show comparable levels to e3 HHcy groups, which would lead one to

113

expect elevated levels of vascular pathology under HHcy conditions, as shown in previous
studies 107, 133, 153. However, we observe the opposite, with the e4 HHcy group having less
pathology and lower levels of MMPs. Further, we show that sex is a key variable in the effects of
the HHcy diet. In almost every measure, we observe significant sex differences, commonly
within the e3 HHcy group.
It was our anticipation that ApoE e4 mice would have an exacerbated response to the
induction of HHcy, given the robust inflammatory response and cerebrovascular pathology we
have previously observed in C57/BL6 mice 107, 133, 153. Instead, our data suggest that ApoE e4 is
associated with a limited microglial response. There were several unexpected findings when
HHcy was induced in ApoE e4 mice as compared to ApoE e3 mice. Most notably, the ApoE e4
mice did not show the same extent of elevated plasma Hcy levels in response to the diet,
comapred ApoE e3 mice or normal C57/BL6 mice 107, 133. Also, there was limited cerebrovascular
pathology in response to the diet. In contrast, ApoE e3 mice responded to the HHcy condition in
a manner comparable to our previous reported findings in C57/BL6 mice 107, 133, 153. Interestingly,
in the control diet groups, ApoE e4 controls showed significant differences compared to e3
controls throughout the study. It has previously been observed that e4 carriers are more prone
to vascular dysfunction and pathology 157, 167. In particular, breakdown of the blood brain barrier,
increased permeability, and elevated levels of MMP9 have been identified in ApoE e4 carriers
157

. This is supported by further findings associating cerebral microbleeds specifically with the

presence of ApoE e4 167. As a result, these outcomes are not wholly unexpected, though we are
unsure why the overall number of bleeds was not more significantly different. It is possible that
ApoE e4 Control mice had insufficient compensatory action against the microhemorrhages
compared to ApoE e3 mice. The basal levels of MMP2, TIMP2, and IL1b are all elevated, some
significantly, in e4 controls over e3 controls, with MMP14 and MMP9 trending toward the same
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relationship. Coupled with the trends of both cortical and hippocampal microglial activation
being elevated in e4 controls over e3 controls, this suggests a basal environment more prone to
developing vascular pathology in e4 mice.
Metabolic differences driven by ApoE isoforms are widespread and well documented 168, 169.
However, no work that we are aware of has probed the transulfuration pathway or 1-C
metabolism related to homocysteine in the context of ApoE isoform differences; though some
studies have looked at the incidence of ApoE e4 and Hcy, with conflicting results 170, 171. Ravaglia
et al. showed human e4 carriers had a lower association with elevated plasma Hcy and a higher
level of C-reactive protein, a common marker of generalized inflammation used clinically.
Nilsson et al. showed the opposite association, with e4 being linked to higher levels of plasma
Hcy, though their study was a smaller scale and had limitations in terms of age-matching of
groups that may have biased the results. We show significant differences in a number of
metabolites in the transsulfuration pathway, as well as methylation metabolites necessary for
the conversion of Hcy back to methionine. Significant differences in plasma Hcy levels show that
the diet was effective in inducing HHcy, yet ApoE e4 mice accumulated less Hcy in the plasma
than e3 mice. Previous studies have shown that both Hcy and ApoE bind VLDL 170, with e4
binding most readily amongst the ApoE isoforms 172, 173. These studies also showed ApoE
genotype dependent changes in VLDL processing and clearance that may in turn alter Hcy levels
in the blood 170. It is possible that the VLDL binding and clearance differences account for the
differences in Hcy accumulation, however we did not have sufficient samples to assess this.
Betaine has been associated with improved resistance against development of HHcy 174, due to
its role in the conversion of Hcy back into methionine. It is significantly elevated in the e4 HHcy
mice over e3 HHcy mice, suggesting this may be another potential mechanism by which Hcy
accumulation was limited.
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Differences between plasma and midbrain tHcy metabolites were also interesting, as they
showed a distinct difference in tHcy levels with no significant differences being observed in the
tissue compared to plasma, which showed pronounced elevation inHHcy groups. The ratio of
SAM to SAH is an indicator of methylation capacity as SAM is a global methyl donor, important
in DNA methylation 175, and SAH is an inhibitor of SAM activity, meaning a lower ratio indicates
lower methylation capacity or downregulation of methyltransferase activity. The e3 HHcy group
had a significantly lower SAM/SAH ratio than all other groups. This suggests that methylation
may be impaired in the brain tissue of the e3 HHcy mice compared to their e4 counterparts.
We observed minor sex differences in terms of tissue metabolite levels, but more
pronounced differences in the plasma levels of some metabolites. In addition to a relatively
small sample size for the females of each group, it is important to note that previous studies
utilizing the HHcy diet in our lab have shown more severe attrition in females than males, both
in terms of mortality rate and severe weight loss; which in turn necessitates early euthanasia of
the animal, a trend which did continue in this study. This attrition may be causing a survival bias
within the data, with only the more resilient females actually making it to the end of the study.
We are also cautious to not overstate the sex difference observations given our relatively low
sample size. Future studies will be powered sufficiently to address sex differences.
Human studies of ApoE and vascular pathology have shown that e4 individuals are more
prone to developing vascular pathologies 156, 157. However, our data shows that the e3 HHcy mice
had significantly more microhemorrhages in the cortex than e4 HHcy mice. Coupled with our
metabolite data, this seems to suggest that e4 mice may have some level of protection from
HHcy induced vascular pathology. While clinically relevant, HHcy is not the most prevalent
etiology of VCID in humans 176, and, thus, may not have been well represented in previous
clinical studies of VCID with a variety of etiologies. Most human VCID and small vessel disease is
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driven by chronic hypertension 177, rather than persistent oxidative stress, which is the
mechanism by which our diet exerts pathology. Nonetheless, evidence of a protective role for
ApoE4 against HHcy is potentially a clinically relevant finding for those who suffer from HHcy.
Prussian staining for hemosiderin, a sensitive histological measure of microhemorrhages,
also showed a sharp sex difference in terms of microhemorrhages, with males having more
cortical and hippocampal bleeds in most groups, though not significantly in all cases. In addition
to the metabolic sex differences observed, which may have limited the extent of pathology, the
female mice used for this study were young enough to still be estrogen cycling, which has been
shown to provide protection from vascular pathology 178, 179.
We considered the possibility that observed decreases in microglial response in e4 mice may
have decreased in response to hemorrhagic events. This in turn may have led to limited
formation of hemosiderin, a by-product of microglial processing of iron-complexes present in
red blood cells that leak into the brain parenchyma in the event of a bleed. Since Prussian
staining identifies hemosiderin deposits, and microglia or macrophages are required for the
conversion of hemoglobin to hemosiderin, it is possible that the decreased microglial response
in e4’s may obfuscate our ability to identify bleeds using Prussian staining. To address this,
albumin staining was performed to visualize vessels and identify areas of bleeding or leakage
independent of hemosiderin deposition. Quantitative assessment was not possible due to
inconsistent perfusion of some animals resulting in entire regions-worth of vessels stained with
excessive albumin, hindering standardized quantification of staining. Qualitative assessment of
albumin staining showed no significant discrepancies between areas of hemosiderin deposition
and vessel leakage, however more quantitative assessment of vascular changes in animals is
merited to ensure this is the case. Future studies may utilize a tetramethylindocarbocynaide
perchlorate dye that interacts with endothelial cells and can be used to identify both leaks and
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angiogenic sprouts 180. This approach focuses on the vessel walls rather than the lack/presence
of albumin, which relies on consistent complete perfusion and also provides additional
information about potential sites of angiogenesis.
One of the most robust differences observed in the NanoString panel was a serine protease
inhibitor, SERPINA3N. Previous research has shown a role for SERPINA3N in neuroprotection 181,
182

, with polymorphisms being associated independently with Alzheimer’s disease 183,

Parkinson’s disease 184, and progressive multiple sclerosis 185. SERPINA3N encodes a1antichymotrypsin (ACT), acutely inhibits chymotrypsin and cathepsin G, serving as a modulator
of inflammation and complement activation 186. Follow-up qPCR quantification of SERPINA3N
levels in the hippocampus verified a genotype dependent upregulation of the gene in e4 mice.
This genotype dependence has been observed previously 146. Previous research has also shown
that this elevation is brain specific, with levels in the blood being decreased in e4s and levels in
the liver being equivalent 146. However, we also observed a reduction in expression in e4 Hcy
compared to e4 controls. It is unclear how Hcy is decreasing SERPINA3N expression in e4 mice,
though it is consistent with the decreased inflammatory signaling observed throughout this
study.
Our results suggest that APOE genotype may affect the vulnerability of an individual to
developing hyperhomocysteinemia. This has been shown in a previous study with one showing
decreased levels of HHcy in the APOE e4 group 170. e4 mice seemed to accumulate lower levels
of homocysteine in their plasma, though we did not track food consumption over the course of
the study to ensure this was not merely the result of genotype dependent differences in food
consumption. In addition, our results suggest a differential role for APOE e3 and APOE e4 in the
development of vascular pathology in response to an oxidative stress such as that induced by
Hcy. There is also a differential basal state of inflammation based on ApoE isoform, as
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demonstrated by our e3 and e4 control differences throughout. Further, sex differences within
each genotype effect some forms of pathology and inflammation. Finally, while Serpina3n was
expressed in a genotype dependent manner, the presence of Hcy led to a decrease in
expression, suggesting a possible abrogation of its ability to modulate cathepsin G mediated
inflammation. Coupled with the sex differences, this would suggest that treatment paradigms
may need to be adjusted at the clinical level to account for ApoE genotype and sex differences.
The muted response of homozygous e4 mice in our study mirrors results also observed in
preliminary human studies performed in our lab. Clinical attempts to manipulate
neuroinflammatory responses as a therapeutic approach to neurodegenerative diseases will
likely need to take these differences into account both in terms of treatment paradigms, but
also when assessing results and efficacy of drugs.
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Figure 1: Induction of hyperhomocystienemia is limited in ApoE4/4 mice. (a) Pathway illustrating
relevant homocysteine metabolic pathways. Group-wise comparisons independent of sex were
performed for plasma levels of (b) total homocysteine (tHcy), (c) cystathionine, and (d) betaine.
Groups were then separated based on sex in order to assess sex dependent effects on the
plasma levels of (e) total homocysteine (tHcy), (f) cystathionine, and (g) betaine. Data are
presented as the median and interquartile range, overlaid with individual data points. All
comparisons by each-way Wilcoxon test. Comparisons denoted with *, **, and *** have pvalues < 0.05, 0.01, and 0.005, respectively.
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Figure 2: Accumulation of homocysteine in the parenchyma of the brain is impaired by the
presence of ApoE4. Group-wise comparisons independent of sex were performed for midbrain
tissue levels of (a) total homocysteine (tHcy), (b) cystathionine, (c) betaine, (d) S-adenosyl
homocysteine, and (e) S-adenosyl methionine. (f) S-adenosyl methionine to S-adenosyl
homocysteine ratios were calculated for each subject as a measure of methylation capacity.
Data are presented as the median and interquartile range, overlaid with individual data points.
All comparisons by each-way Wilcoxon test. Comparisons denoted with *, **, and *** have pvalues < 0.05, 0.01, and 0.005, respectively.
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Figure 3: Related metabolites of homocysteine accumulate in brain tissue in a sex dependent
manner. Groups were separated based on sex in order to assess sex dependent effects on the
midbrain tissue levels of (a) total homocysteine, (b) cystathionine, (c) S-adenosyl methionine,
and (d) S-adenosyl homocysteine. (e) S-adenosyl methionine to S-adenosyl homocysteine ratios
were calculated for each subject as a measure of methylation capacity. Data are presented as
the median and interquartile range, overlaid with individual data points. All comparisons by
each-way Wilcoxon test. Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01,
and 0.005, respectively.
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Figure 4: ApoE4 mice given homocysteine diet develop fewer cortical microhemorrhages than
ApoE3 mice under the same treatment. Average microhemorrhages per section for (a) cortical
and (b) hippocampal were calculated for each group. Additionally, the average area of staining
for each section in the (c) cortical and (d) hippocampal regions was calculated and then
compiled for each group. Data are presented as the median and interquartile range, overlaid
with individual data points. All comparisons by each-way Wilcoxon test. Comparisons denoted
with *, **, and *** have p-values < 0.05, 0.01, and 0.005, respectively. Representative image of
a (e)cortical and (f) hippocampal microhemorrhages are shown at 20x magnification.
Microhemorrhage is shown as blue staining on neutral red counterstaining.
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Figure 5: Expression of MMPs 2, 9, & 14 and TIMP2 is elevated in ApoE3/3 Homocysteine mice
in a sex dependent manner. RT-qPCR results for each group independent of sex are shown for
hippocampal expression of (a) TIMP2, (b) MMP2, (c) MMP9, & (g) MMP14. Sex dependent
comparisons of (d) TIMP2, (e) MMP2, & (f) MMP9 are also shown. Data are presented as the
median fold change relative to the ApoE3 group and interquartile range, overlaid with individual
data points. All comparisons by each-way Wilcoxon test. Comparisons denoted with *, **, and
*** have p-values < 0.05, 0.01, and 0.005, respectively. Dotted line denotes a fold change of 1.
(h) Diagram showing relationships between MMPs and TIMPs, and connections to inflammation
and blood brain barrier breakdowns.
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Figure 6: Microglia are more activated in ApoE3/3 homocysteine mice than ApoE4/4
homocysteine mice. Percentage of IBA-1 staining within the (a) frontal cortical and (b)
hippocampal regions for each group independent of sex are shown. The ratio of activated
microglia to total microglia for the (c) frontal cortical and (d) hippocampal regions for each
group is shown as well. Most data are presented as the median and interquartile range, overlaid
with individual data points, with all comparisons by each-way Wilcoxon test. IBA-1 Cortical %
area data are presented as mean and standard deviation, with comparisons by each way T-test.
Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005, respectively. (e)
Representative IBA-1 staining in the hippocampus of respective animals. Images taken at 10x
magnification.
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Figure 7: Inflammatory markers are elevated in ApoE3/3 homocysteine and ApoE4/4 control
mice while Serpina3n is elevated in a genotype dependent manner. RT-qPCR results for each
group independent of sex are shown for hippocampal expression of (a) CD86, (b) IL1b, (c) TNFa,
(d) ApoE, (e) Arc, and (f) Serpina3n. Sex dependent comparisons of (g) ApoE and (e) Serpina3n
are also shown. Data are presented as the median fold change relative to the ApoE3 group and
interquartile range, overlaid with individual data points. All comparisons by each-way Wilcoxon
test. Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005,
respectively. Dotted line denotes a fold change of 1.
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Supplemental Figure 1: Plasma homocysteine and methylation metabolites and comparisons
shown independent of sex. Concentrations for (a) S-adenosyl methionine, (b) S-adenosyl
homocysteine, (c methionine), (d) choline, and (e)the S-adenosyl methionine to S-adenosyl
homocysteine ratio of each group independent of sex is shown. Data are presented as the
median and interquartile range, overlaid with individual data points. All comparisons by eachway Wilcoxon test. Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01, and
0.005, respectively.
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Supplemental Figure 2: Plasma homocysteine and methylation metabolites and comparisons
accounting for sex are shown. Concentrations for (a) S-adenosyl methionine, (b) S-adenosyl
homocysteine, (c) methionine), (d) choline, and (e)the S-adenosyl methionine to S-adenosyl
homocysteine ratio of each group accounting for sex is shown. Data are presented as the
median and interquartile range, overlaid with individual data points. All comparisons by eachway Wilcoxon test. Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01, and
0.005, respectively.
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Supplemental Figure 3: Brain tissue homocysteine and methylation metabolites and
comparisons. Concentrations for (a) methionine and (b) choline in each group are shown,
independent of sex. Brain tissue levels of (c) methionine), (d) choline, and (e)betaine of each
group accounting for sex are shown. Data are presented as the median and interquartile range,
overlaid with individual data points. All comparisons by each-way Wilcoxon test. Comparisons
denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005, respectively.
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Supplemental Figure 4: RT-qPCR results for the expression of MMP3, TIMP1, and MMP14. Fold
changes for (a) MMP3 and (b) TIMP1 expression relative to ApoE3 Control, independent of sex,
are shown. Sex dependent fold change comparisons for (c) MMP14, (d) MMP3, and (e) TIMP1
are also shown. Data are presented as the median fold change relative to the ApoE3 group and
interquartile range, overlaid with individual data points. All comparisons by each-way Wilcoxon
test. Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005,
respectively. Dotted line denotes a fold change of 1.
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Supplemental Figure 5: RT-qPCR results showing expression fold change of multiple
neuroinflammatory related genes independent of sex. RT-qPCR results for each group
independent of sex are shown for hippocampal expression of (a) IL1rn, (b) Tgfb1, (c) BCas1, (d)
Fos, (e) Lrrc3, (f) Nthl1, and (g) TREM2. Data are presented as the median fold change relative to
the ApoE3 group and interquartile range, overlaid with individual data points. All comparisons
by each-way Wilcoxon test. Comparisons denoted with *, **, and *** have p-values < 0.05,
0.01, and 0.005, respectively. Dotted line denotes a fold change of 1.
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Supplemental Figure 6: RT-qPCR results showing expression fold change of multiple
neuroinflammatory related genes accounting for sex. RT-qPCR results for each group accounting
for sex are shown for hippocampal expression of (a) CD86, (b) IL1b, (c) IL1rn, (d) Tgfb1, (e)
TNFa, (f) Arc, (g) BCas1, (h) Fos, (i) Lrrc3, (j) Nthl1, and (k) TREM2. Data are presented as the
median fold change relative to the ApoE3 group and interquartile range, overlaid with individual
data points. All comparisons by each-way Wilcoxon test. Comparisons denoted with *, **, and
*** have p-values < 0.05, 0.01, and 0.005, respectively. Dotted line denotes a fold change of 1.
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Supplemental Figure 7: Female mice of each group are resistant to developing
microhemorrhages. Average microhemorrhages per section for (a) cortical and (b) hippocampal
were calculated for each group, accounting for sex. Additionally, the average area of staining for
each section in the (c) cortical and (d) hippocampal regions was calculated and then compiled
for each group, accounting for sex. Data are presented as the median and interquartile range,
overlaid with individual data points. All comparisons by each-way Wilcoxon test. Comparisons
denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005, respectively.
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Supplemental Figure 8: ApoE4/4 mice show sex dependent differences in microglial area both
under control and hyperhomocystienemic conditions. Percentage of IBA-1 staining within the (a)
frontal cortical and (b) hippocampal regions for each group, accounting for sex, are shown. The
ratio of activated microglia to total microglia for the (c) frontal cortical and (d) hippocampal
regions for each group is shown as well. Data are presented as the median and interquartile
range, overlaid with individual data points. All comparisons by each-way Wilcoxon test.
Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01, and 0.005, respectively.
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Supplemental Figure 9: Sex dependent astrocyte differences are present in both the ApoE3/3
homocysteine and ApoE4/4 control mice. Percentage of GFAP staining within the hippocampus
for each group (a) independent of sex and (b) accounting for sex are shown. Data are presented
as the median and interquartile range, overlaid with individual data points. All comparisons by
each-way Wilcoxon test. Comparisons denoted with *, **, and *** have p-values < 0.05, 0.01,
and 0.005, respectively. (c) Representative GFAP staining in the hippocampus of respective
animals at 10x magnification.

136

Supplemental Table 1:
Group Layout

ApoE3/3

ApoE4/4

Control

Male
N = 10

Female
N=4

Male
N = 12

Female
N=4

Homocysteine

Male
N = 16

Female
N =4

Male
N = 10

Female
N=5

Supplemental Table 2: RT-qPCR Probe List and Information
Thermo Fisher – appliedbiosystems
Probe Target
(Waltham, MA, USA) Assay ID #
ApoE
Mm01307193_g1
Arc
Mm01204954_g1
Bcas1
Mm00659626_m1
CD86
Mm00444543_m1
Fos
Mm00487425_m1
Mm00434228_m1
IL1b
IL1rn
Mm00446186_m1
Lrrc3
Mm00728659_s1
MMP2
Mm00439498_m1
MMP3
Mm00440295_m1
MMP9
Mm00442991_m1
MMP14
Mm00485054_m1
Nthl1
Mm00476559_m1
Serpina3n
Mm00776439_m1
Tgfb1
Mm01178820_m1
TIMP1
Mm01341361_m1
TIMP2
Mm00441825_m1
Mm00443258_m1
TNFa
TREM2
Mm04209424_g1
18s
Hs99999901_s1
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Supplemental Table 3: NanoString Differential Expression: E3 Control vs. E4
Control
Probe
Effect Size
P-value
Q-value
Expression in
E3 Relative to
E4
Rps9
-0.8291
2.2372 E-07
0.0001
DOWN
Serpina3n
-1.7214
6.9484 E-06
0.0027
DOWN
Gpr183
-0.3817
0.0005
0.1278
DOWN
Tspan18
0.3708
0.0007
0.1278
UP
Bid
0.4092
0.0020
0.3088
UP
Il1r1
0.4194
0.0035
0.4613
UP
Pllp
-0.6151
0.0056
0.5703
DOWN
Tnfrsf25
0.3998
0.0064
0.5703
UP
Bcas1
-0.6831
0.0066
0.5703
DOWN
Nthl1
-0.3273
0.0108
0.8458
DOWN
Arc
0.5646
0.0119
0.8506
UP
Plekhb1
-0.5627
0.0166
0.8688
DOWN
Mog
-0.5889
0.0166
0.8688
DOWN
Chn2
-0.5341
0.0189
0.8688
DOWN
Grin2a
0.3380
0.0224
0.8688
UP
Plxnb3
-0.4462
0.0238
0.8688
DOWN
Tnfsf4
-0.5985
0.0244
0.8688
DOWN
Opalin
-0.5347
0.0246
0.8688
DOWN
Npnt
0.3142
0.0264
0.8688
UP
Fos
0.4227
0.0270
0.8688
UP
Cnp
-0.5098
0.0283
0.8688
DOWN
Pmp22
-0.4308
0.0321
0.8688
DOWN
Gzma
0.3330
0.0321
0.8688
UP
Mag
-0.5021
0.0459
0.8982
DOWN
Tmem88b
-0.5083
0.0467
0.8982
DOWN
Asb2
-0.3154
0.0499
0.8982
DOWN
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Supplemental Table 4: NanoString Differential Expression: E3 Homocysteine vs.
E4 Homocysteine
Probe
Effect Size
P-value
Q-value
Expression in
E3 Relative to
E4
Rps9
-0.5511
0.0003
0.2462
DOWN
Bdnf
-0.5361
0.0037
0.8200
DOWN
Agt
0.9582
0.0076
0.8200
UP
Trem2
0.3358
0.0087
0.8200
UP
Serpina3n
-0.8762
0.0143
0.8200
DOWN
Lrrc3
0.4938
0.0198
0.8200
UP
Tnfrsf25
-0.4257
0.0248
0.8200
DOWN
Arhgap24
0.4427
0.0281
0.8200
UP
Lcn2
0.4297
0.0378
0.8200
UP
S100b
0.3802
0.0388
0.8200
UP
Cyp27a1
0.3514
0.0422
0.8200
UP
Optn
0.3732
0.0497
0.8200
UP
Supplemental Table 5: NanoString Differential Expression: E3 Homocysteine vs.
E3 Control
Probe
Effect Size
P-value
Q-value
Expression in
Hcy Relative
to Control
Bik
0.5017
0.0036
0.9940
UP
Lag3
0.5026
0.0044
0.9940
UP
Tnfrsf4
0.4499
0.0074
0.9940
UP
Trem1
0.4038
0.0108
0.9940
UP
Pilrb1
-0.4025
0.0119
0.9940
DOWN
Nlrp3
-0.3139
0.0145
0.9940
DOWN
Tnfrsf25
-0.4261
0.0211
0.9940
DOWN
Tnfsf4
0.5658
0.0316
0.9940
UP
Lcn2
0.5833
0.0334
0.9940
UP
Bcas1
0.5037
0.0345
0.9940
UP
Pllp
0.4327
0.0361
0.9940
UP
Slamf9
0.3296
0.0366
0.9940
UP
Prkcq
0.4518
0.0411
0.9940
UP
Gria2
-0.3017
0.0439
0.9940
DOWN
Gzma
-0.3087
0.0494
0.9940
DOWN
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Supplemental Table 6: NanoString Differential Expression: E4 Homocysteine vs.
E4 Control
Probe
Effect Size
P-value
Q-value
Expression in
Hcy Relative
to Control
Cxcl9
0.3589
0.0032
0.7957
UP
Npnt
0.3813
0.0104
0.7957
UP
Grin2a
0.3734
0.0112
0.7957
UP
Arc
0.5890
0.0112
0.7957
UP
Lig1
-0.3395
0.0122
0.7957
DOWN
Prkar2b
-0.4931
0.0146
0.7957
DOWN
Atf3
0.3370
0.0152
0.7957
UP
Nthl1
-0.4057
0.0163
0.7957
DOWN
Tnfrsf25
0.4101
0.0175
0.7957
UP
Serpina3n
-1.0375
0.0180
0.7957
DOWN
Lrrc3
-0.5209
0.0183
0.7957
DOWN
Abcc3
-0.3571
0.0193
0.7957
DOWN
Prkacb
-0.4601
0.0255
0.7957
DOWN
Il1r1
0.3579
0.0275
0.7957
UP
Stmn1
-0.4522
0.0311
0.7957
DOWN
Pmp22
-0.4219
0.0334
0.7957
DOWN
Itgax
-0.3061
0.0350
0.7957
DOWN
Cd36
-0.5040
0.0411
0.7957
DOWN
Cd109
0.3239
0.0411
0.7957
UP
Slc17a6
-0.7917
0.0497
0.7957
DOWN
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